Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care

Bridget Candy; Louise Jones; Victoria Vickerstaff; Philip J Larkin; Patrick Stone

doi:10.1002/14651858.CD006332.pub3

. 2018 Jun 5;2018(6):CD006332. doi: 10.1002/14651858.CD006332.pub3

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care

Bridget Candy ^1,^✉, Louise Jones ¹, Victoria Vickerstaff ¹, Philip J Larkin ², Patrick Stone ³

Editor: Cochrane Pain, Palliative and Supportive Care Group

PMCID: PMC6513061 PMID: 29869799

Abstract

Background

Opioid‐induced bowel dysfunction (OIBD) is characterised by constipation, incomplete evacuation, bloating, and gastric reflux. It is one of the major adverse events of treatment for pain in cancer and in palliative care, resulting in increased morbidity and reduced quality of life.

This is an update of two Cochrane reviews. One was published in 2011, Issue 1 on laxatives and methylnaltrexone for the management of constipation in people receiving palliative care; this was updated in 2015 and excluded methylnaltrexone. The other was published in 2008, Issue 4 on mu‐opioid antagonists (MOA) for OIBD. In this updated review, we only included trials on MOA (including methylnaltrexone) for OIBD in people with cancer and people receiving palliative care.

Objectives

To assess the effectiveness and safety of MOA for OIBD in people with cancer and people receiving palliative care.

Search methods

We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, CINAHL, and Web of Science to August 2017. We also searched clinical trial registries and regulatory websites. We contacted manufacturers of MOA to identify further data.

Selection criteria

We included randomised controlled trials (RCTs) that assessed the effectiveness and safety of MOA for OIBD in people with cancer and people at a palliative stage irrespective of the type of terminal disease they experienced.

Data collection and analysis

Two review authors assessed risk of bias and extracted data. The appropriateness of combining data from the trials depended upon sufficient homogeneity across the trials. Our primary outcomes were laxation, impact on pain relief, and adverse events. Impact on pain relief was a primary outcome because a possible adverse effect of MOAs is a reduction in pain relief from opioids. We assessed the evidence on these outcomes using GRADE.

Main results

We identified four new trials for this update, bringing the total number included in this review to eight. In total, 1022 men and women with cancer irrespective of stage or at a palliative care stage of any disease were randomised across the trials. The MOAs evaluated were oral naldemedine and naloxone (alone or in combination with oxycodone), and subcutaneous methylnaltrexone. The trials compared with MOA with a placebo or with the active intervention administered at different doses or in combination with other drugs. The trial of naldemedine and the two of naloxone in combination with oxycodone were in people with cancer irrespective of disease stage. The trial on naloxone alone was in people with advanced cancer. The four trials on methylnaltrexone were undertaken in palliative care where most participants had cancer. All trials were vulnerable to biases; four were at a high risk as they involved a sample of fewer than 50 participants per arm.

In the trial of naldemedine compared to placebo in 225 participants, there were more spontaneous laxations over the two‐week treatment for the intervention group (risk ratio (RR) 1.93, 95% confidence intervals (CI) 1.36 to 2.74; moderate‐quality evidence). In comparison with higher doses, lower doses resulted in fewer spontaneous laxations (0.1 mg versus 0.2 mg: RR 0.73, 95% CI 0.55 to 0.95; 0.1 mg versus 0.4 mg: RR 0.69, 95% CI 0.53 to 0.89; moderate‐quality evidence). There was moderate‐quality evidence that naldemedine had no effect on opiate withdrawal. There were five serious adverse events. All were in people taking naldemedine (low‐quality evidence). There was an increase in the occurrence of other (non‐serious) adverse events in the naldemedine groups (RR 1.36, 95% CI 1.04 to 1.79, moderate‐quality evidence). The most common adverse event was diarrhoea.

The trials on naloxone taken either on its own, or in combination with oxycodone (an opioid) compared to oxycodone only did not evaluate laxation response over the first two weeks of administration. There was very low‐quality evidence that naloxone alone, and moderate‐quality evidence that oxycodone/naloxone, had no effect on analgesia. There was low‐quality evidence that oxycodone/naloxone did not increase the risk of serious adverse events and moderate‐quality evidence that it did not increase risk of adverse events.

In combined analysis of two trials of 287 participants, we found methylnaltrexone compared to placebo induced more laxations within 24 hours (RR 2.77, 95% CI 1.91 to 4.04. I² = 0%; moderate‐quality evidence). In combined analysis, we found methylnaltrexone induced more laxation responses over two weeks (RR 9.98, 95% CI 4.96 to 20.09. I² = 0%; moderate‐quality evidence). The proportion of participants who had a rescue‐free laxation response within 24 hours of the first dose was 59.1% in the methylnaltrexone arms and 19.1% in the placebo arm. There was moderate‐quality evidence that the rate of opioid withdrawal was not affected. Methylnaltrexone did not increase the likelihood of a serious adverse event; there were fewer in the intervention arm (RR 0.59, 95% CI 0.38 to 0.93; I² = 0%; moderate‐quality evidence). There was no difference in the proportion of participants experiencing an adverse event (RR 1.17, 95% CI 0.94 to 1.45; I² = 74%; low‐quality evidence). Methylnaltrexone increased the likelihood of abdominal pain and flatulence.

Two trials compared differing methylnaltrexone schedules of higher doses with lower doses. For early laxation, there was low‐quality evidence of no clear difference between doses on analgesia and adverse events. Both trials measured laxation response within 24 hours of first dose (trial one: RR 0.82, 95% CI 0.41 to 1.66; trial two: RR 1.07, 95% CI 0.81 to 1.42).

Authors' conclusions

In this update, the conclusions for naldemedine are new. There is moderate‐quality evidence to suggest that, taken orally, naldemedine improves bowel function over two weeks in people with cancer and OIBD but increases the risk of adverse events. The conclusions on naloxone and methylnaltrexone have not changed. The trials on naloxone did not assess laxation at 24 hours or over two weeks. There is moderate‐quality evidence that methylnaltrexone improves bowel function in people receiving palliative care in the short term and over two weeks, and low‐quality evidence that it does not increase adverse events. There is a need for more trials including more evaluation of adverse events. None of the current trials evaluated effects in children.

Plain language summary

Mu‐opioid antagonists for bowel dysfunction due to opioids in people with cancer and people receiving palliative care

Background

Opioids (morphine‐like drugs) are used to treat severe pain. Unfortunately, they cause side effects. Opioid‐induced bowel dysfunction (OIBD) is a term used to describe constipation, incomplete evacuation of the bowels, bloating, and increased reflux (flowing back) of stomach contents. OIBD may be so severe that a person chooses to limit opioid treatment to improve bowel function. OIBD is common in people with cancer and people receiving palliative care (care given to people with a terminal illness when a cure is no longer possible). Laxatives are often the first‐choice treatment for OIBD. They may not always work. Mu‐opioid antagonists (MOA) are specific medicines for OIBD. Clinical guidelines may recommend them when laxatives fail.

Trial characteristics

The aim of this updated review was to determine what we know about the effectiveness and safety of MOA for the management of OIBD in people with cancer and people receiving palliative care and for whom laxatives have failed. A possible side effect of an MOA is reduced pain relief from opioids; therefore, we looked at its impact on pain relief. We only included randomised controlled trials (RCTs), which are well‐designed clinical trials that provide the most reliable evidence. RCTs needed to evaluate an MOA, such as the medicines naldemedine, methylnaltrexone, and naloxone. The trial comparison groups could be a placebo (a substance with no known active effect), usual care, or another treatment such as a different type of MOA.

Key results

Our search to August 2017 found eight trials involving 1022 adults. The MOAs evaluated in people with cancer were oral naldemedine and naloxone taken in combination with an opioid treatment (for pain). Methylnaltrexone given by injection was evaluated in palliative care where most participants had advanced cancer.

The results were naldemedine or methylnaltrexone compared with placebo. For naloxone, they were either in comparison with a placebo or with opioid treatment only.

We rated the quality of the evidence from studies as very low to moderate. Very low means that we are very uncertain about the results. High means that we are very confident in the results. There were problems with the design of studies, including under‐reporting of trial methods.

Bowel movements within 24 hours and up to two weeks

There was moderate‐quality evidence that naldemedine increased bowel movements up to two weeks. Trials did not measure the effects of naloxone on bowel movements at two weeks. Methylnaltrexone increased bowel movements or laxations (softer stools) within 24 hours and up to two weeks (moderate‐quality evidence).

Pain relief

There was moderate‐quality evidence that naldemedine did not change pain relief. Trials did not measure pain intensity with naldemedine. There was very low‐quality evidence that naloxone taken on its own did not change pain relief. There was moderate‐quality evidence that naloxone taken with an opioid treatment did not change pain relief. There was moderate‐ to low‐quality evidence that methylnaltrexone did not change pain relief.

Risk of serious side effects (hospitalisation, life‐threatening, or fatal) and other side effects

There was low‐quality evidence that naldemedine and naloxone in combination with an opioid treatment did not increase the risk of serious side effects. For naldemedine, there were five serious side effects in the trial, although none were described as relating to the study drug. Methylnaltrexone probably did not increase the risk of serious side effects (moderate‐quality evidence).

There was moderate‐quality evidence that naldemedine increased the risk of side effects. There was moderate‐quality evidence that naloxone taken with oxycodone (an opioid painkiller) did not increase the risk of side effects. There was low‐quality evidence that methylnaltrexone did not increase the overall risk of a side effect. Methylnaltrexone increased the risk of abdominal pain and flatulence.

Conclusion

There was moderate‐quality evidence to suggest that naldemedine improved bowel function over two weeks in adults with cancer and OIBD but increased the risk of side effects; and that methylnaltrexone improved bowel function in people receiving palliative care and low‐quality evidence that methylnaltrexone did not increase side effects. The results of this review need to be interpreted with caution as they were not obtained from high‐quality evidence. There were no studies in children.

Summary of findings

Background

This review is a (partial) update of two previously published reviews in The Cochrane Database of Systematic Reviews.

Mu‐opioid antagonists for opioid‐induced bowel dysfunction, 2008, Issue 2 (McNicol 2008).
Laxatives or methylnaltrexone for the management of constipation in palliative care patients, 2011, Issue 1 (Candy 2011).

This review update presented the findings on the effectiveness and safety of mu‐opioid antagonists (MOA) for opioid‐induced bowel dysfunction (OIBD) in people with cancer and people receiving palliative care. An updated review on laxatives for the management of constipation in people receiving palliative care has been published (Candy 2015). It is planned that evidence on the effectiveness on MOAs for OIBD in other populations, including, for example, people with chronic non‐malignant pain, will be reviewed in a subsequent Cochrane Review.

Description of the condition

Opioids, such as morphine sulphate, oxycodone, and fentanyl, are potent analgesics. They are recommended by the World Health Organization (WHO) and are in clinical guidelines for the management of moderate‐to‐severe pain from cancer and other populations such as people needing palliative care (WHO 2016). They are widely used, although globally there is wide variation suggesting an under‐utilisation of opioids for pain management in some locations (Manjiani 2014).

However, opioids are associated with adverse events. The most common and disabling of these is bowel dysfunction, which can be severe enough for a person to limit their opioid use (Cook 2008). Opioids, regardless of the method of administration (oral, parenteral, transdermal), interfere with gastrointestinal propulsive motility (Leppert 2010). Opioids increase absorption of fluids from the intestine and decrease epithelial secretion. They delay gastric emptying and decrease peristalsis in the gut.

OIBD has been described as, "A change when initiating opioid therapy from baseline bowel habits that is characterised by any of the following: reduced bowel movement frequency (conventionally less than 3 per week), development or worsening of straining to pass bowel movements, a sense of incomplete rectal evacuation, or harder stool consistency" (Kumar 2012). It may even lead to stool impaction (Camilleri 2014). In addition to constipation, OIBD describes a constellation of symptoms including bloating, abdominal distention, gastric reflux, abdominal cramping, dry mouth, epigastric fullness, nausea, and vomiting (Leppert 2015; Pappagallo 2001). It can cause psychological distress and agitation in terminally ill people. OIBD increases health service use, sometimes necessitates hospitalisation, and it can dramatically reduce an already compromised quality of life. It may lead to people undertreating their pain (Pizzi 2012); however, since the dose that produces constipation may only be 25% of that required for adequate analgesia, dose reduction is not an appropriate option for management of OIBD (Ketwaroo 2013).

Estimated incidence of OIBD in hospice populations and people with advanced disease is high from 65% to 90% (Panchal 2007; Sykes 1998). Although these estimates are relatively old, there is no evidence to suggest that this is no longer the case.

Description of the intervention

The recommended preventive treatment of OIBD in palliative care and advanced disease is the use of a laxative stimulant and a stool softener, in addition to general measures such as increased food, fibre‐rich diet, fluid intake, physical activity, and privacy during defecation (NICE 2012). However, these measures are not always effective; in people taking opioids, it is estimated that over 80% of people remain constipated despite regular use of laxatives (Coyne 2014; Diego 2011).

MOAs, such as methylnaltrexone, naloxone, and naloxegol, are designed specifically to target the pathophysiology of OIBD by 'neutralising' the constipating effect of the opioid. Methylnaltrexone is licensed for the treatment of opioid‐induced constipation in palliative care in more than 50 countries (Bader 2013). In clinical guidelines, where methylnaltrexone is considered, it is described to act as an augmentation to laxatives or as an alternative when laxatives fail (European Association of Palliative Care, Caraceni 2012), and should be used only under advice from a specialist palliative care clinician (Scottish Palliative Care Guidelines 2014). It is important to note that the National Institute for Health and Care Excellence (NICE) is unable to recommend the use in the UK National Health Service (NHS) of methylnaltrexone for treating OIBD in people with advanced illness receiving palliative care because no evidence submission was received from the manufacturer of the technology (NICE 2013).

How the intervention might work

Opioids mediate their gastrointestinal and analgesic effects through the same subclasses of opioid receptors in the human body: mu, kappa, and delta. How each receptor type is involved in OIBD is not fully understood (Neefjes 2014). The peripheral opioid effect on mu‐opioid receptors in the gut wall may play a main role in OIBD (Leppert 2010). Co‐ordination of motility is disrupted by activation of the mu‐opioid receptors that inhibit excitatory and inhibitory neural pathways within the enteric nervous system.

One approach for dissociation of the analgesia effect of opioids is to separate the opioid's central activity from its peripheral activity (Wang 2013). This may be achieved with a peripherally acting opioid receptor antagonist with limited ability to cross the blood‐brain barrier and which therefore does not interfere with analgesia (Brown 1985). Alternatively, this can be achieved by use of a preparation that undergoes extensive 'first‐pass' metabolism by the liver and so does not enter the systemic circulation.

There are several mu‐antagonists in use and others in development. Naloxone is commercially available; it is centrally acting but has a narrow therapeutic effect with certain doses reversing desirable analgesia (Camilleri 2011). It undergoes extensive first‐pass metabolism and in the correct dosage it does not reverse the analgesic effect of opioids. It is administered orally. The development of a prolonged‐release preparation of naloxone to allow as much cover of the small and large intestine as possible when used with oxycodone has led to further studies of the compound (Camilleri 2011). There are several other preparations that do not cross the blood‐brain barrier and these include alvimopan, methylnaltrexone, naloxegol, and naldemedine. Alvimopan has a high affinity for peripheral opioid receptors. It is only recommended for short‐term use, such as postsurgery, because of the possibility of myocardial events (Merck 2015). It is contraindicated in people with advanced disease (Leppert 2015). Methylnaltrexone is less lipid soluble than naloxone and, therefore, less likely to cross the blood‐brain barrier. It is only currently available in subcutaneous formulation. Naloxegol, which is administered orally, has a polyethylene glycol moiety that limits its capacity to cross the blood‐brain barrier (Pritchard 2015). Naldemedine is a derivative of naloxone. There are limited published details on its mechanisms of action, it is currently being evaluated in phase III trials in people with cancer.

Why it is important to do this review

There are reviews of MOAs for OIBD across different populations (e.g. Ford 2013). However, it is important to evaluate their effectiveness specifically in cancer and in palliative care populations (Bader 2012; Clark 2014). This is because of the differences inherent in these groups that may impact, in a likely negative way, on the effect of an MOA. The impact may differ because of the multi‐factorial pathophysiology of constipation in people with cancer and advanced diseases (Leppert 2010). This may include structural abnormalities such as bowel obstruction; pelvic tumours; radiation fibrosis; or metabolic disturbances such as dehydration, hypercalcaemia, and hypokalaemia. It may involve neurological disorders. There may also be general issues increasing the risk and complicating the management of OIBD such as advanced age, depression, drug sedation, chemotherapy, multiple therapies, and a lack of privacy provided as an inpatient for bowel evacuation. As the person's disease progresses, they may have increasing frailty, lower activity, reduced appetite, and eventually multiple organ failure, all of which may impact on bowel function (Bader 2012). Moreover, because of these factors, people with cancer and particularly people at a palliative care stage may have a higher risk than other, less ill populations of experiencing adverse events from an MOA.

Objectives

To assess the effectiveness and safety of MOAs for OIBD in people with cancer and people receiving palliative care.

Methods

Criteria for considering studies for this review

Types of studies

We included double‐blind, randomised controlled trials (RCTs) that investigated the efficacy of MOAs for OIBD. We did not include open‐label extension phases of trials or post‐hoc analyses of trials because they are at an increased risk of bias. We applied no language restrictions. We required full journal publication. In addition to trials presented in full journal publication, we included any online clinical trial results summaries of otherwise unpublished trial data relating to the published trial.

Types of participants

Eligible trials concerned participants of any age or either sex who were:

people with cancer or people at a palliative stage irrespective of disease and age, or both;
all or the majority (over 95%) of people on a stable opioid regimen and had OIBD that had not resolved from taking laxatives.

We included trials of populations of participants where not all fitted our eligibility criteria so long as at least 50% of the sample were people with cancer or people receiving palliative care or at an advanced stage of their disease or where they provided subgroup analysis in either of these participant groups.

We did not include trials of any populations if the MOAs for bowel dysfunction were for associated postoperative ileus (arrest of intestinal peristalsis). This is because this is not caused primarily by opioids (Marderstein 2008). We also excluded trials of healthy volunteers, participants with constipation because of drug misuse, and participants with constipation arising from bowel obstruction.

Types of interventions

We included trials of interventions evaluating mu‐receptor opioid antagonists that were either peripherally or systemically acting, and administered at any dose and by any route. These included, for example, methylnaltrexone and naloxone.

The comparator intervention of interest was a different MOA, an alternative pharmacological or non‐pharmacological intervention, a placebo, or no treatment.

Types of outcome measures

Primary outcomes

Our primary outcomes of interest were efficacy in regards to laxation response and safety.

Efficacy:
- laxation response in the first 24 hours and between days one and 14 after first dose. Laxation response could have been measured using a validated scale such as the 3‐item Bowel Function Index (BFI) on ease of defecation or person feeling of incomplete bowel emptying;
- effect on analgesia. This could have been measured as analgesic requirements, opioid withdrawal symptoms, and pain intensity. This was a primary outcome as MOAs may have an adverse effect on pain relief.
Safety:
- serious adverse events;
- number and type of adverse events.

Secondary outcomes

Number of participants who dropped out due to adverse events.
Other measures of laxation response, such as bowel transit time and relief at a time‐point beyond day 14.
Relief of other constipation‐associated symptoms, such as abdominal pain and loss of appetite.
Use of rescue medication for laxation. This is the need for additional medication because relief from constipation has not occurred within an acceptable time, such as for instance within four hours of administration of the intervention subcutaneous methylnaltrexone. Rescue medication may be in the form of a laxative suppository or an enema.
Quality of life, participant satisfaction with bowel movements, and participant preference.

Search methods for identification of studies

Electronic searches

For this update, we searched five databases.

CENTRAL (CRSO) 2007 to issue 7 of 12 2017.
MEDLINE and MEDLINE in process (Ovid) 2007 to 28 August 2017.
Embase (Ovid) 2007 to week 35 2017.
CINAHL (EBSCO) 1982 to August 2017.
Web of Science (SCI‐Expanded and CPCI‐S) 1945 to 28 August 2017.

The search strategies are listed in Appendix 1.

Searching other resources

We searched three clinical trials registries to March 2016.

The metaRegister of controlled trials (mRCT) (www.controlled‐trials.com/mrct).
ClinicalTrials. gov (clinicaltrials.gov).
The WHO International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/).

We searched two regulatory agency websites, US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for drug reports.

We searched pharmaceutical companies' websites of known manufacturers of MOAs to identify trial data.

We searched two pharmaceutical company trials registers:

AstraZeneca Clinical Trials (www.astrazenecaclinicaltrials.com);
GlaxoSmithKline Clinical Trial Register (www.gsk‐clinicalstudyregister.com).

We checked references lists of included trials and any identified systematic reviews. We also undertook a forward citation search of all included trials. We checked conference proceedings of the National Cancer Research Institute (NCRI) Cancer Conference and the European Association of Palliative Care (EAPC). We contacted authors of any identified relevant conference abstracts to ask for full details of their trials.

We wrote to pharmaceutical companies of known manufacturers of MOAs to obtain any trial data not available in peer‐review publications; these were AstraZeneca, Mundipharma GmbH, Progenics, Shionogi, and Valeant. For this purpose, we adapted a letter developed by authors of a previous Cochrane Review; see Appendix 2 for a copy of this letter.

Data collection and analysis

Selection of studies

Two review authors (BC, LJ) independently screened the citations identified in the database searches. Where it was unclear or likely that the studies fulfilled our inclusion criteria, we retrieved the full‐text articles. If disagreements on eligibility had occurred, we would have resolved them by discussion, or if persistent, by a third review author (PS). If necessary for further clarification such as if it was unclear whether the trial identified was completed and whether their findings were available, we sought contact with the author or sponsor.

Data extraction and management

We extracted data (as detailed in Types of outcome measures) from each trial. One review author (BC) extracted the data and another review author checked them (LJ/VV). We resolved disagreements by discussion, or if persistent, we would have involved a third review author (PS).

Assessment of risk of bias in included studies

Two review authors (BC, VV) independently assessed risk of bias for each trial using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions, resolving any disagreements by discussion (Higgins 2011). We completed a 'Risk of bias' table for each included trial. We assessed the following.

Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process: random number table; computer random number generator); and unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process, which were therefore at high risk of bias (odd or even date of birth; hospital or clinic record number).
Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions before assignment determines whether the intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); and unclear risk of bias if the method was not clearly stated. We excluded trials that did not conceal allocation, which were therefore at high risk of bias (open list).
Blinding of participants and personnel (performance bias and detection bias). We assessed the methods used to blind trial participants and personnel (performance bias) and outcome assessors (detection bias) from knowledge after trial assignment of which intervention a participant received. We assessed the methods as: low risk of bias if the trial stated that it was blinded and described the method used to achieve blinding: identical tablets, matched in appearance and smell; and unclear risk of bias if the trial stated that it was blinded but did not provide an adequate description of how blinding was achieved. We judged a trial as high risk if blinding was attempted but it was likely that the blinding could have been broken and that the outcome was likely to be influenced by lack of blinding. We did not include any trial that was reported as not being double blinded.
Incomplete outcome data (attrition bias). We assessed whether there was attrition bias due to the amount, nature, or handling of incomplete outcome data. We judged the trial as having low risk of attrition bias if there were no missing outcome data or the reasons for missing data were unlikely to be related to true outcome, or missing data and reasons for it were similar across trial arms, or the missing data had been imputed using appropriate methods. We judged the trial as high risk if the reason for missing outcome data was likely to be related to the outcome, with either imbalance across trial arms in numbers of reasons for missing data and if an inappropriate application of simple imputation was potentially used. We judged the trial as unclear risk if there was insufficient reporting of attrition to permit judgement of low or high risk.
Selective outcome reporting (checking if there was a selection of a subset of the original variables recorded on the basis of the results). We assessed selective outcome reporting, if a protocol was available, by comparing outcomes in the protocol and published report. If they were the same we assessed it as low risk in this domain, if they differed, we considered it as high risk. If a protocol was not available, then we compared the outcomes listed in the methods section of an article with the outcomes for which results were reported. If they differed, we considered the trial as high risk. If a protocol was not available and even though the outcomes listed in the methods section and the results section were the same, we considered the trial as having an unclear risk of bias in this domain. Since not all trials have a protocol available, we expected to find a number of trials in this review to be at unclear risk.
Sample size (checking for possible biases confounded by small sample size). Small trials have been shown to overestimate treatment effects, probably because the conduct of small trials is more likely to be less rigorous, allowing critical criteria to be compromised (Zhang 2013). We considered trials to be at low risk of bias if they had 200 participants or more per treatment arm, at unclear risk if they had 50 to 199 participants per treatment arm, and at high risk if they had fewer than 50 participants per treatment arm.

We incorporated the results of the 'Risk of bias' assessment into the review through systematic narrative description and commentary about each item.

Measures of treatment effect

We reported trial results organised by type of MOA and comparator evaluated. We measured treatment effects using dichotomous data, an ordinal rating scale, or qualitative evidence. For cross‐over trials, we only generated, as appropriate, a risk ratio (RR) or mean difference (MD) for pre‐cross‐over results.

Dichotomous data

For dichotomous data, we generated RRs and their 95% confidence intervals (CIs). For primary outcomes, we calculated numbers needed to treat (NNT) using the 'treat‐as‐one‐trial' method. To indicate direction of effect, we presented results as either number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) to indicate direction of effect.

Continuous data

We assessed effects measures for ordinal data as continuous data. We generated the MD for continuous and ordinal data where the data were provided as a mean and standard deviation (SD).

If baseline data were reported preintervention and postintervention, we reported means or proportions for both intervention and control groups and calculated the change from baseline.

If limitations in the trial data prevented reporting a RR or if continuous data, an MD, we reported the results with caution due to lack of transparency of the evidence.

Qualitative evidence

If there had been any qualitative data in the included trials, we planned to extract them in consultation with the Cochrane Qualitative and Implementation Methods Group. Such qualitative data may aim to capture the participant's views on the value of the intervention.

Unit of analysis issues

In our handling of each trial analytic, we considered issues that may have impacted on findings. For these we took guidance from the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). These were:

groups of participants randomised together with the same intervention (e.g. cluster‐randomised trials);
participants receiving more than one intervention (e.g. cross‐over trials);
multiple observations for the same outcomes (such as repeated measures).

Dealing with missing data

Given the nature of this field, there was a significant amount of missing data as a result of trial attrition due to the death of the participant.

We planned to contact trial authors if we had found data to be missing. For trials using continuous outcomes in which SDs were not reported, and no information was available from the authors, we calculated the SDs using the standard error of the mean (SEM).

Assessment of heterogeneity

We assessed statistical heterogeneity using the I² statistic. The I² statistic is a reliable and robust test to quantify heterogeneity, since it does not depend on the number of trials or on the between‐trial variance. I² measures the extent of inconsistency among trials' results, and can be interpreted as the proportion of total variation in trial estimates that is due to heterogeneity rather than sampling error. We considered an I² value of greater than 50% to indicate substantial heterogeneity (Deeks 2006). Where possible, we undertook subanalyses or sensitivity analyses in an attempt to explain heterogeneity.

Assessment of reporting biases

To reduce the risk of reporting bias, we undertook comprehensive database and registry searches, including searches of clinical trial registers and drug regulatory agency websites. We also searched websites of, and wrote to, pharmaceutical companies that are known manufacturers of MOAs to identify trial data.

Owing to an insufficient number of included studies (fewer than 10), as appropriate a test power was not ensured; we did not create funnel plots or conduct Egger's test for funnel plot asymmetry (Egger 1997; Sterne 2011). In applying in combined analysis as appropriate random‐effects estimates of the intervention effect, we decided not to exclude small studies, as this might have led to an inappropriate reduction of studies in a field that is just emerging. Nevertheless, in case of small‐study effects, we cautiously considered sample size when grading and discussing the evidence for each outcome (Roberts 2015). We expect that in updates of the review, when more studies have been published, we will be able to explore reporting biases further by comparing fixed‐effect and random‐effects estimates or L'Abbé plots as a visual method of assessing differences in results of individual studies.

Data synthesis

Where trial data were of sufficient quality and sufficiently similar (in diagnostic criteria, intervention, outcome measure, length of follow‐up, and type of analysis), we combined data in a meta‐analysis to provide a pooled effect estimate. We used a fixed‐effect model in the first instance. If we found no statistical heterogeneity, we used a random‐effects model to check the robustness of the fixed‐effect model. If there was substantial (over 50%) statistical heterogeneity, we reported the random‐effects model only. Where this occurred, we stated we used the random‐effects model.

Subgroup analysis and investigation of heterogeneity

Where heterogeneity was identified in a meta‐analysis, we undertook subgroup and sensitivity analysis to investigate its possible sources. Subgroup analysis explores whether the overall effect varied with different trial populations, and with the nature and content of the interventions. In this update, we planned the following subgroup analysis:

studies of participants with advanced disease or in palliative care, as impact of MOAs may differ in such participants than those at an earlier stage of cancer.

Sensitivity analysis

If sufficient trials were available, we sought to perform, in a meta‐analysis, sensitivity analyses to explore the influence of:

publication status by excluding unpublished trials;
trial quality by excluding trials that had a high risk of bias;
use of appropriate measures/validated measures of outcome by excluding trials that did not use appropriate/validated measures.

We presented in a table for ease of comparisons such investigations of heterogeneity.

Quality of evidence

Two review authors (BC, VV) independently rated the quality of the primary outcomes. We used the GRADE system to rank the quality of the evidence using the guidelines provided in Chapter 12.2 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

The GRADE system uses the following criteria for assigning a quality level to a body of evidence (Chapter 12, Higgins 2011).

High: randomised trials; or double‐upgraded observational studies.
Moderate: downgraded randomised trials; or upgraded observational studies.
Low: double‐downgraded randomised trials; or observational studies.
Very low: triple‐downgraded randomised trials; or downgraded observational studies; or case series/case reports.

The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence.

High: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.
Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

Factors that may decrease the quality level of a body of evidence are:

limitations in the design and implementation of available studies suggesting high likelihood of bias;
indirectness of evidence (indirect population, intervention, control, outcomes);
unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses);
imprecision of results (wide CIs);
high probability of publication bias (0.7854 to 1.1359).

Factors that may increase the quality level of a body of evidence are:

large magnitude of effect;
all plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results show no effect;
dose‐response gradient.

We decreased the grade rating by one (‐1) or two (‐2) (up to a maximum of ‐3 to 'very low') if we identified:

serious (‐1) or very serious (‐2) limitation to study quality;
important inconsistency (‐1);
some (‐1) or major (‐2) uncertainty about directness;
imprecise or sparse data (‐1);
high probability of reporting bias (‐1).

In certain circumstances, we adjusted the overall rating for a particular outcome as recommended by GRADE guidelines (Guyatt 2013a). For example, we considered whether there were so few data that the results were highly susceptible to the random play of chance, or if a study used last observation carried forward imputation in circumstances where there were substantial differences in adverse event withdrawals, one would have no confidence in the result and would need to downgrade the quality of the evidence by three levels to very low quality (Guyatt 2013b). In other circumstances, we would not downgrade for imprecision if CIs were wide, if the outcome threshold according to how much harm would be acceptable given a benefit or vice versa.

'Summary of findings' table

We included 'Summary of findings' tables to present the main findings in a transparent and simple tabular format. We have summarised the level of overall quality of evidence on all primary outcomes in the 'Summary of findings' tables. This does not include quality evaluations on the individual types of adverse events. This decision was made as we were not judging quality for all types of adverse events using GRADE; we were only judging those adverse events that were most commonly reported. We included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes laxation response (within 24 hours; between day one and day 14), effect on analgesia (pain intensity, opioid withdrawal), serious adverse events, and number of adverse events.

Results

Description of studies

Results of the search

In this update, we first searched for evidence on 24 September 2014. This search was run without restricting the search terms to only those relating to cancer and palliative care populations. We reran our search to 29 August 2017 updating search terms and restricting to those relating to cancer and palliative care populations. We identified 633 unique citations. See Figure 1 for the flowchart of the screening process.

Included studies

We included seven published RCTs of 976 participants (Ahmedzai 2012; Bull 2015; Katakami 2017; Portenoy 2008; Slatkin 2009; Sykes 1996; Thomas 2008). We included one RCT in a general population with a subset analysis in 46 people with cancer (Dupoiron 2017). We include four trials (Portenoy 2008; Slatkin 2009; Sykes 1996; Thomas 2008) that were identified in the earlier Cochrane Reviews (Candy 2011; McNicol 2008) for which this review forms a partial update. For four trials, we also identified regulatory (FDA and the EMA) assessments of the manufactures' Clinical Study Reports (Ahmedzai 2012; Portenoy 2008; Slatkin 2009; Thomas 2008) (these reports are referenced under Ahmedzai 2012 for oxycodone/naloxone, and Slatkin 2009 for methylnaltrexone).

Seven trials were multi‐centre parallel RCTs. The other was a single‐centre cross‐over controlled trial (Sykes 1996). All trials were sponsored by a pharmaceutical company, apart from Sykes 1996. Included trial populations were from North America (Bull 2015; Portenoy 2008; Slatkin 2009; Thomas 2008), Japan (Katakami 2017), South Korea (Katakami 2017) and the UK (Sykes 1996). Two trials involved sites in multiple countries. In one this included sites in Australia, Czech Republic, France, Germany, Hungary, Israel, the Netherlands, Poland, and the UK (Ahmedzai 2012), and in the other France, Germany, Poland, and the UK (Dupoiron 2017).

Three trials evaluated participants with chronic cancer pain who were not described as being at an advanced disease stage (Ahmedzai 2012; Dupoiron 2017; Katakami 2017). Where specified, the healthcare setting was a clinic (Ahmedzai 2012; Dupoiron 2017).

The five other trials evaluated effects in participants with an advanced disease including cancer, and other conditions such as AIDS or circulatory disease. Although in all these trials the majority had a primary diagnosis of cancer. Three of these trials were based in multiple care settings including inpatients and outpatients of a hospice or hospital, and long‐term care facilities (Bull 2015; Slatkin 2009; Thomas 2008). Another was hospice based only (Sykes 1996), and the other did not report the setting (Portenoy 2008).

In all trials, according to inclusion criteria, at baseline all or the majority (over 95%) of participants were on a stable opioid regimen, had OIBD, and were taking laxatives. Six trials specified that the indication for opioids was pain (Ahmedzai 2012; Dupoiron 2017; Katakami 2017; Portenoy 2008; Slatkin 2009; Thomas 2008). The other trials did not state an indication. All studies were on adults. All trials reported laxative use at baseline. For all it was either the need to take regular laxatives was part of the inclusion criteria, or it was stated that all or the majority (90% or greater) used regular laxatives.

In four trials, the intervention of interest was subcutaneous methylnaltrexone (Bull 2015; Portenoy 2008; Slatkin 2009; Thomas 2008). Three trials tested oral naloxone; in one naloxone only (Sykes 1996) and in two oxycodone (an opioid) in combination with naloxone (Ahmedzai 2012; Dupoiron 2017). The other trial evaluated oral naldemedine (Katakami 2017). We identified no trials in cancer or palliative care populations that evaluated naloxegol or another MOA.

Three of the trials involved multiple trial arms (Katakami 2017; Portenoy 2008; Slatkin 2009), the others were two armed. The interventions were either compared with a placebo or with the active intervention administered at different doses or in combination with other drugs. Outcomes on laxation were measured as self‐report or clinician report, for instance on rescue‐free laxation (Bull 2015; Katakami 2017; Portenoy 2008; Slatkin 2009; Thomas 2008), or by using a validated scale such as the BFI (Ahmedzai 2012; Dupoiron 2017), Patient Assessment of Constipation Symptoms (PAC‐SYM), and the Global Clinical Impression of Change (GCIC) (Slatkin 2009). One trial also used small bowel transit time using a lactulose and hydrogen breath test (Sykes 1996). Further details of these trials are shown in the Characteristics of included studies table.

Five trials involved a subsequent open‐label extension phase (Bull 2015; Portenoy 2008; Slatkin 2009; Sykes 1996; Thomas 2008). We did not report results on effectiveness from open‐label extension as the participants were no longer blinded.

Excluded studies

We excluded five trials because they did not include participants with cancer or at the palliative stage of a disease in their sample. These trials are listed in the Characteristics of excluded studies table.

Ongoing studies

We also identified 11 trials known to have been started but results as yet are not published (Dimitroulis 2014; JAPIC‐CTI‐132340; NCT00135577; NCT00331045/00101998; NCT02745353; NCT02839889; NCT01438567; NCT02321397; NCT02574819; Neefjes 2014; Peppin 2013). Four of these trials are evaluating methylnaltrexone (Dimitroulis 2014; NCT02574819; Neefjes 2014; Peppin 2013), one naldemedine (JAPIC‐CTI‐132340), one oxycodone/naloxone (NCT01438567; NCT02321397), two naloxegol (NCT02745353; NCT02839889), and two alvimopan (NCT00135577; NCT00331045/00101998). Further details of these are in the Characteristics of ongoing studies table.

Studies awaiting classification

We are awaiting classification for one trial on naloxegol (Webster 2013). We are unsure until we receive details from the authors or funders whether the trial fulfils our inclusion criteria. See Characteristics of studies awaiting classification for further details.

Risk of bias in included studies

All trials were vulnerable to a number of biases, most commonly reporting bias and small sample sizes. See Figure 2; Figure 3.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Allocation

The method of randomisation sequence generation was described adequately in four trials (Ahmedzai 2012; Katakami 2017; Slatkin 2009; Thomas 2008). In the other four trials this was inclear as they did not provide any details. The method of concealment of allocation was described adequately in two trials (Ahmedzai 2012; Slatkin 2009). In the other six trials this was unclear as they did not provide any details.

Blinding

Three trials were at a low risk of performance bias and detection bias (Katakami 2017; Slatkin 2009; Thomas 2008). In the other trials, it was unclear as they provided no details on who was blinded or how blinding was conducted.

Incomplete outcome data

The risk of attrition bias was low in most trials apart from one trial where it was unclear how many had dropped out of the subgroup of people with cancer (Dupoiron 2017).

Selective reporting

The risk of selective reporting was unclear in seven trials as there were no published protocols. One of these trials did not state a primary outcome (Sykes 1996).The eighth study had low risk of bias as it had a protocol (Dupoiron 2017).

Other potential sources of bias

We assessed sample size. Four trials were at a high risk of biased results as they involved fewer than 50 participants in at least one trial arm (Dupoiron 2017; Portenoy 2008; Slatkin 2009; Sykes 1996). In one of these trials, only a subset of their study sample was relevant to this review (Dupoiron 2017). Also in one of these trials while there were fewer than 50 participants in one of their treatments arms, as we combined in our exploration of the impact of MOAs their two treatment groups in comparison with placebo this risk was no longer apparent (Slatkin 2009).

All the other trials were at an unclear risk of bias as they involved treatment arms with between 50 and 199 participants.

Effects of interventions

See: Table 1; Table 2; Table 3; Table 4; Table 5; Table 6

Summary of findings for the main comparison. Naldemedine compared to placebo for opioid‐induced bowel dysfunction in cancer and people receiving palliative care.

Naldemedine compared to placebo for opioid‐induced bowel dysfunction in cancer and people receiving palliative care
Patient or population: people with cancer and people receiving palliative care with opioid‐induced bowel dysfunction Settings: cancer care Intervention: naldemedine Comparison: placebo
Outcomes	*Illustrative comparative risks (95% CI)**		Relative effect  (95% CI)	No of participants  (studies)	Quality of the evidence  (GRADE)	Comments
	Assumed risk	Corresponding risk
	Placebo	Naldemedine
Laxation response within 24 hours of dose	—	—	—	—	—	Not reported
Laxation response between day 1 and day 14^a	375 per 1000	724 per 1000  (510 to 1000)	RR 1.93 (1.36 to 2.74) NNTB 2.88 (2.04 to 4.92)	225 (1 study)	⊕⊕⊕⊝ Moderate^b	—
Effect on analgesia: opioid withdrawal^c	—	—	0.1 mg: MD ‐0.13 (‐0.57 to 0.31); 0.2 mg: MD ‐0.40 (‐0.87 to 0.07); 0.4 mg: MD ‐0.02 (‐0.45 to 0.41)	225 (1 study)	⊕⊕⊕⊝ Moderate^b	—
Effect on analgesia: pain intensity	—	—	—	—	—	Not reported
Serious adverse events^a	—	—	5 SAEs occurred, all in naldemedine group.	225 (1 study)	⊕⊕⊝⊝  Low^b,d	—
Adverse events^a	518 per 1000	704 per 1000 (539 to 927)	RR 1.36 (1.04 to 1.79)	225 (1 study)	⊕⊕⊕⊝ Moderate^b	—
The basis for the assumed risk* (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; MD: mean difference; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio; SAE: serious adverse events.
GRADE Working Group grades of evidence  High quality: we are very confident that the true effect lies close to that of the estimate of the effect.  Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.  Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.  Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

Open in a new tab

^aMeasured by clinician or self‐report and in the case of adverse events using severity grades according to the Common Terminology Criteria for Adverse Events.  ^bDowngraded by one level for limitations to the study design due to unclear risk of bias (reporting bias).  ^cMeasured by Clinical Opiate Withdrawal Scale.  ^dDowngraded by one level for imprecision due to limited number of events.

Summary of findings 2. Lower‐dose naldemedine compared to higher‐dose naldemedine for opioid‐induced bowel dysfunction in cancer and people receiving palliative care.

Lower‐dose naldemedine compared to higher‐dose naldemedine for opioid‐induced bowel dysfunction in cancer and people receiving palliative care
Patient or population: people with cancer and people receiving palliative care with opioid‐induced bowel dysfunction Setting: cancer care Intervention: lower dose naldemedine 0.1 mg daily Comparison: higher dose naldemedine 0.2 mg or 0.4 mg daily
Outcomes	*Illustrative comparative risks (95% CI)**		Relative effect  (95% CI)	No of participants  (studies)	Quality of the evidence  (GRADE)	Comments
	Assumed risk	Corresponding risk
	Higher dose 0.2 mg/0.4 mg daily	Lower dose 0.1 mg daily
Laxation response within 24 hours of dose	—	—	—	—	—	Not reported
Laxation response between day 1 and day 14^a	0.1 mg vs 0.2 mg: 776 per 1000 0.1 mg vs 0.4 mg: 821 per 1000	0.1 mg vs 0.2 mg: 564 per 1000 (430 to 739) 0.1 mg vs 0.4 mg: 564 per 1000 (433 to 733)	0.1 mg vs 0.2 mg: RR 0.73 (0.55 to 0.95) 0.1 mg vs 0.4 mg: RR 0.69 (0.53 to 0.89)	226 (1 study) 0.1 mg vs 0.2 mg: n = 113 0.1 mg vs 0.4 mg: n = 111	⊕⊕⊕⊝ Moderate^b	—
Effect on analgesia: opioid withdrawal	—	—	—	—	—	Not reported
Effect on analgesia: pain intensity	—	—	—	—	—	Not reported
Serious adverse events	—	—	—	—	—	Not reported
Adverse events	—	—	—	—	—	Not reported
The basis for the assumed risk* (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence  High quality: we are very confident that the true effect lies close to that of the estimate of the effect.  Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.  Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.  Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

Open in a new tab

^aMeasured by self‐report.  ^bDowngraded by one level for limitations to the study design due to unclear risk of bias (reporting bias).

Summary of findings 3. Naloxone compared with placebo for cancer and people receiving palliative care with opioid‐induced bowel dysfunction.

Naloxone compared with placebo for cancer and people receiving palliative care with opioid‐induced bowel dysfunction
Patient or population: people with cancer and people receiving palliative care with opioid‐induced bowel dysfunction Settings: cancer care Intervention: naloxone Comparison: placebo
Outcomes	Illustrative comparative risks*		Relative effect	No of participants  (studies)	Quality of the evidence  (GRADE)	Comments
	Assumed risk	Corresponding risk
	Placebo	Naloxone
Laxation response within 24 hours of a dose	—	—	—	—	—	Not reported
Laxation response between day 1 and day 14	—	—	—	—	—	Not reported
Effect on analgesia: opioid withdrawal	—	—	—	—	—	Not reported
Effect on analgesia: pain intensity^a	—	—	No statistical difference in pain experienced when taking placebo or naloxone. Full data, including pre‐cross‐over results, were not provided.	17 (1 study)	⊕⊝⊝⊝  Very low^b	—
Serious adverse events	—	—	—	—	—	Not reported
Adverse events	—	—	—	—	—	Not reported
The basis for the assumed risk* (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
GRADE Working Group grades of evidence  High quality: we are very confident that the true effect lies close to that of the estimate of the effect.  Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.  Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.  Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

Open in a new tab

^aMeasured using 4‐point scale (0 = no pain, 3 = severe pain).  ^bDowngraded by three levels due to evidence from one study with a small sample size, which was a cross‐over study with no drug washout between cross‐over, and unclear risk of reporting bias.

Summary of findings 4. Oxycodone/naloxone prolonged release tablets compared with oxycodone prolonged‐released tablets for opioid‐induced bowel dysfunction.

Oxycodone/naloxone prolonged release tablets compared with oxycodone prolonged‐released tablets for opioid‐induced bowel dysfunction
Patient or population: people with cancer and people receiving palliative care with opioid‐induced bowel dysfunction Settings: cancer care Intervention: oxycodone/naloxone prolonged‐release tablets Comparison: oxycodone prolonged‐released tablets
Outcomes	*Illustrative comparative risks (95% CI)**		Relative effect	No of participants  (studies)	Quality of the evidence  (GRADE)	Comments
	Assumed risk	Corresponding risk
	Oxycodone	Oxycodone/naloxone
Laxation response within 24 hours of dose	—	—	—	—	—	Not reported
Laxation response between day 1 and day 14	—	—	—	—	—	Not reported
Effect on analgesia: opioid withdrawal^c	—	—	Intervention group: mean 6.64 (SD 5.97) comparison group: mean 7.29 (SD 4.59) at 7 days	184 (1 study)	⊕⊕⊕⊝ Moderate^b	—
Effect on analgesia: pain intensity^a	—	—	Intervention group: mean 3.50 (SD 1.88) and comparison group: mean 3.52 (SD 1.80) at 4 weeks	184 (1 study)	⊕⊕⊕⊝ Moderate^b	Another study, Dupoiron 2017 also found outcome to be similar between trial arms, but did not provide any data.
Serious adverse events	43 per 1000	87 per 1000 (27 to 279)	RR 2.00 (95% CI 0.62 to 6.41)	184 (1 study)	⊕⊕⊝⊝ Low^b,d	—
Adverse events	754 per 1000	815 per 1000 (709 to 935)	RR 1.08 (95% CI 0.94 to 1.24)	234 (2 studies)	⊕⊕⊕⊝ Moderate^b	—
The basis for the assumed risk* (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio; SD: standard deviation.
GRADE Working Group grades of evidence  High quality: we are very confident that the true effect lies close to that of the estimate of the effect.  Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.  Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.  Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

Open in a new tab

^aMeasured using the Brief Pain Inventory‐Short Form.  ^bDowngraded by one level because of study limitations (unclear risk of reporting bias).  ^cMeasured using the Modified Subjective Opiate Withdrawal Scale.  ^dDowngraded by one level due to imprecision because of wide confidence intervals.

Summary of findings 5. Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in cancer and people receiving palliative care.

Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in cancer and people receiving palliative care
Patient or population: people with cancer and people receiving palliative care with opioid‐induced bowel dysfunction Setting: palliative care Intervention: methylnaltrexone Comparison: placebo
Outcomes	*Anticipated absolute effects (95% CI)**		Relative effect  (95% CI)	No of participants  (studies)	Quality of the evidence  (GRADE)	Comments
Outcomes	Risk with placebo	Risk with methylnaltrexone	Relative effect  (95% CI)	No of participants  (studies)	Quality of the evidence  (GRADE)	Comments
Laxation response within 24 hours of dose^a	195 per 1000	568 per 1000  (431 to 695)	RR 2.77 (1.91 to 4.04)	287  (2 studies)	⊕⊕⊕⊝ Moderate^b	—
Laxation response between day 1 and day 14 (specifically within 4 hours after 4 or more of the 7 doses)^a	52 per 1000	517 per 1000  (330 to 699)	RR 9.98 (4.96 to 20.09)	305  (2 studies)	⊕⊕⊕⊝ Moderate ^b,c	—
Effect on analgesia: opioid withdrawal^d	Study 1: day 1: MD 0.00 (‐0.46 to 0.46); day 14: MD 0.10 (‐0.63 to 0.83) Study 2: median change to day 2 = 0 in both trials arms			236 (2 studies)	⊕⊕⊕⊝ Moderate^b	‐
Effect on analgesia: pain intensity^e	Study 1: at 4 hours (methylnaltrexone 0.15 mg/kg: MD ‐0.76 (‐1.47 to 0.05); methylnaltrexone 0.3 mg/kg: MD ‐0.25 (‐0.91 to 0.41) Study 2: at day 1 and 14 (day 1: MD 0.20 (‐0.62 to 1.02); day 14: MD ‐0.70 (‐1.52 to 0.12)			287 (2 studies)	⊕⊕⊝⊝ Low^b,f	Another study, Bull 2015, found similar pain intensity experienced in trial arms, full data not provided.
Serious adverse events	238 per 1000	142 per 1000  (88 to 219)	RR 0.59 (0.38 to 0.93)	364  (2 studies)	⊕⊕⊕⊝ Moderate^b	—
Adverse events	700 per 1000	815 per 1000  (745 to 869)	RR 1.17 (CI 0.94 to 1.45)	518  (3 studies)	⊕⊕⊝⊝ Low^b,g	Heterogeneity was substantial (74%). It was explained in sensitivity analysis by omitting the trial at a high risk of bias because of small sizes. The effect estimate was reduced. The direction of effect not changed.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; MD: mean difference; RR: risk ratio.
GRADE Working Group grades of evidence  High quality: we are very confident that the true effect lies close to that of the estimate of the effect.  Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.  Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Open in a new tab

^aMeasured by self‐report or clinician report.  ^bDowngraded once for study limitations because of unclear risk of reporting bias.  ^cWe did not downgrade for imprecision due to wide confidence intervals because the effect size was large.

^dMeasured using the modified Himmelsbach Opioid Withdrawal Scale.  ^eMeasured by participant‐rated scale 0‐10.  ^fDowngraded once for inconsistency because of differing estimates of effect.  ^gDowngraded once for inconsistency because statistical heterogeneity was high across trials.

Summary of findings 6. Lower‐dose methylnaltrexone compared to higher‐dose methylnaltrexone for opioid‐induced bowel dysfunction in cancer and people receiving palliative care.

Lower dose methylnaltrexone compared to higher dose for opioid‐induced bowel dysfunction in cancer and people receiving palliative care
Patient or population: people with cancer and people receiving palliative care with opioid‐induced bowel dysfunction Setting: palliative care Intervention 1: lower‐dose methylnaltrexone (study 1: 3 doses, 1 week, 1 mg; study 2: 1 dose, 0.15 mg/kg) Intervention 2: higher‐dose methylnaltrexone (study 1: 3 doses, 1 week, 5‐12.5 mg; study 2: 1 dose, 0.30 mg/kg)
Outcomes	*Illustrative comparative risks (95% CI)**		Relative effect  (95% CI)	No of participants  (studies)	Quality of the evidence  (GRADE)	Comments
	Assumed risk	Corresponding risk
	Higher dose	Lower dose
Laxation response within 24 hours of first dose^a	Study 1: 609 per 1000 Study 2: 639 per 1000	Study 1: 499 per 1000 (250 to 100) Study 2: 681 per 1000 (515 to 904)	Study 1: RR 0.82 (0.41 to 1.66) Study 2: RR 1.07 (0.81 to 1.42)	135 (2 studies) Study 1: n = 33 Study 2: n = 102	⊕⊕⊝⊝ Low^b	Unable to combine study data as methylnaltrexone low and higher doses differed per trial
Laxation response^a	At 3 days: 706 per 1000	At 3 days: 332 per 1000  (127 to 882)	At 3 days: RR 0.47 (0.18 to 1.25)	33 participants (1 study)	⊕⊕⊝⊝ Low^b	Unable to combine study data as methylnaltrexone low and higher doses differed per trial
Laxation response^a	At 5 days: 688 per 1000	At 5 days: 144 per 1000  (21 to 901)	At 3 days: RR 0.21 (0.03 to 1.31)	33 participants (1 study)	⊕⊕⊝⊝ Low^b
Effect on analgesia: opioid withdrawal^c	—	—	MD ‐0.04 (‐0.73 to 0.65)	102 participants (1 study)	⊕⊕⊝⊝ Low^b	Another study,Portenoy 2008, also found outcome to be similar between trial arms, but did not provide any data
Effect on analgesia: pain intensity^d	—	—	MD ‐0.51 (‐1.49 to 0.47)	102 participants (1 study)	⊕⊕⊝⊝ Low^b	Another study, Portenoy 2008, also found outcome to be similar between trial arms, but did not provide any data
Serious adverse event	—	—	—	—		Not reported
Adverse event	Study 1: 1000 per 1000 Study 2: 800 per 1000	Study 1: 1000 per 1000 (1000 to 1000) Study 2: 723 per 1000 (580 to 902)	Study 1: RR 1.00 (1.00 to 1.00) Study 2: RR 0.90 (0.73 to 1.13)	135 (2 studies) Study 1: n = 33 Study 2: n = 102	⊕⊕⊝⊝ Low^b	Unable to combine study data as methylnaltrexone low and higher doses differed per trial
The basis for the assumed risk* (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; MD: mean difference; RR: risk ratio.
GRADE Working Group grades of evidence  High quality: we are very confident that the true effect lies close to that of the estimate of the effect.  Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.  Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.  Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

Open in a new tab

^aMeasured by clinician or self‐report.

^bDowngraded by two levels for study limitations: one for unclear risk of bias (reporting bias) and one for small sample size (high risk of bias).

^cMeasured using the modified Himmelsbach Opioid Withdrawal Scale.

^dMeasured by participant‐rated scale 0‐10.

The trials varied in population (participants with any disease at a palliative stage or people with cancer irrespective of disease stage), intervention, and how they reported the outcomes. This limited the number of combined analyses. Subgroup and sensitivity analyses were limited because of the small number of trials included in any combined analysis. We have standardised the results where possible and reported the findings in the trials as fully as possible.

Naldemedine

One trial of 225 participants with cancer evaluated the effectiveness of two weeks of treatment with naldemedine compared with placebo and at different doses in people with cancer irrespective of disease stage (Katakami 2017). Doses of naldemedine were 0.1 mg, 0.2 mg, or 0.4 mg daily. Overall, we rated the quality of the evidence on laxation, effect on analgesia, and adverse events as moderate. See Table 1.

Primary outcomes

Laxation response

The study did not measure laxation response within the first 24 hours following the first drug dose and participant evaluation of improvement in bowel function.

In comparison with placebo, naldemedine increased the number of participants who had spontaneous bowel movements over the two‐week treatment phase (RR 1.93, 95% CI 1.36 to 2.74. NNTB 3, 95% CI 2 to 5). We judged the quality of evidence for laxation response within two weeks to be moderate. We downgraded the quality of evidence by one level for limitations to the study design. This was because of unclear risk of bias (reporting bias).

The proportion of participants who had a rescue‐free laxation response over the two weeks differed by dose of naldemedine, with the higher dose resulting in more laxations (0.1 mg: 56.4%; 0.2 mg: 77.6%; 0.4 mg: 82.1%). All these were clear improvements when compared with placebo, which had a laxation responder rate of 37.5% (0.1 mg: P = 0.0464; 0.2 mg: P = 0.001; and 0.4 mg: P = 0.001). There was a dose difference in laxation response. This was in comparison with higher doses (0.2 mg and 0.4 mg) the dose of 0.1 mg daily resulted in fewer spontaneous bowel movements (0.1 mg versus 0.2 mg: RR 0.73, 95% CI 0.55 to 0.95; 0.1 mg versus 0.4 mg: RR 0.69, 95% CI 0.53 to 0.89). There was no clear difference between the dose of 0.2 mg daily compared to 0.4 mg daily in bowel movements (RR 0.95, 95% CI 0.79 to 1.14). We judged the quality of evidence on dose response to be moderate. We downgraded the quality of evidence by one level for limitations to the study design. This was because of unclear risk of bias (reporting bias).

Effect on analgesia

Naldemedine had no effect on analgesia compared with placebo in that there was no noticeable increase in opiate withdrawal over two weeks (0.1 mg: MD ‐0.13, 95% CI ‐0.57 to 0.31; 0.2 mg: MD ‐0.40, 95% ‐0.87 to 0.07; 0.4 mg: MD ‐ 0.02, 95% CI ‐0.45 to 0.41). The study did not measure the effect on analgesia using pain intensity. We judged the quality of evidence for effect on analgesia (opioid withdrawal) to be moderate. We downgraded the quality of evidence by one level for limitations to the study design. This was because of unclear risk of bias (reporting bias).

Serious adverse events

There were five serious adverse events. All events occurred in the naldemedine group. One participant experienced a gastrointestinal bleed (taking naldemedine 0.1 mg); one participant each experienced pneumonia, anaemia, or asthenia. One participant died due to bile duct cancer. The investigator considered the death unrelated to the study drug. Judgments on whether the other events were related to the study drug were not reported. Four of the serious adverse events occurred in the highest dose (0.4 mg). We judged the quality of evidence for serious adverse events to be low. We downgraded the quality of evidence by two levels, one for limitations to the study design and one for imprecision. This was because of unclear risk of bias (reporting bias) and a limited number of events.

Number and type of adverse events

There was a clear difference in the proportion of participants in the intervention arm compared to participants in the placebo arm who experienced an adverse event (RR 1.36, 95% CI 1.04 to 1.79). We judged the quality of evidence that naldemedine increased the risk of an adverse event to be moderate. We downgraded the quality of evidence by one level for limitations to the study design. This was because of unclear risk of bias (reporting bias).

The most common adverse event was diarrhoea. There was no clear difference in the proportion of participants in the intervention arm compared to participants in the placebo arm who experienced diarrhoea (RR 1.58, 95% CI 0.97 to 2.57). For eight of the participants receiving naldemedine, the diarrhoea was moderate and in another participant, it was severe. Diarrhoea in participants in the placebo group was mild. Other adverse events reported/measured included white blood cell count, abdominal pain, nausea, and vomiting (see Table 7).

1. Adverse events reported 2% of more participants in the trial of naldemedine.

Adverse event	Naldemedine (%)	Placebo (%)
Diarrhoea	67 (39)	14 (25)
Decreased WBC count	9 (5)	3 (5)
Abdominal pain	6 (4)	0 (0)
Vomiting	5 (3)	0 (0)
Bone marrow failure	3 (2)	2 (4)
Decreased appetite	6 (4)	1 (2)
Nasopharyngitis	4 (2)	1 (2)
Nausea	4 (2)	4 (7)
Rash	3 (2)	2 (4)
Decreased platelet count	3 (2)	0 (0)
Decreased total protein	7 (4)	1 (2)
Glucose in urine	4 (2)	1 (2)
Abnormal haematology test	2 (1)	0 (0)
Decreased RBC count	4 (2)	0 (0)
Hypertension	2 (1)	0 (0)
Increased blood alkaline phosphatase	4 (2)	1 (2)
Increased blood lactate dehydrogenase	2 (1)	1 (2)
Increased blood pressure	2 (1)	0 (0)
Increased blood urea	4 (2)	1 (2)
Increased WBC count	1 (2)	2 (4)
Protein present in urine	5 (3)	0 (0)
Upper abdominal pain	3 (2)	1 (2)

Open in a new tab

RBC: red blood cell; WBC: white blood cell.

All comparisons were not statistically significant.

Secondary outcomes

Number of participants who dropped out due to adverse events

There was no clear difference in the proportion of participants who dropped out due to an adverse event between participants taking naldemedine and participants taking placebo (RR 2.68, 95% CI 0.34 to 20.98).

Other measures of laxation response

The trial did not report other measures of laxation response.

Relief of other constipation‐associated symptoms

The trial did not report relief of other constipation‐associated symptoms.

Use of rescue medication for laxation

The trial did not measure use of 'rescue' medication for laxation.

Quality of life, satisfaction with bowel movements, and participant preference

The trial did not report quality of life, satisfaction with bowel movements, and participant preference.

Naloxone

One cross‐over trial evaluated the effectiveness of oral naloxone compared with placebo in 17 participants with advanced cancer (Sykes 1996). The participants received two days on either placebo or naloxone followed (without washout) by another two days on the trial agent that was not received on day one and two. Naloxone was given four‐hourly for a total daily dose of 0.5%, 1%, 2%, 5%, 10%, or 20% of the total daily dose of morphine. Overall, we rated the quality of the evidence on effect on analgesia as very low (laxation and adverse events not reported). See Table 3.

Primary outcomes

Laxation response

The trial did not measure laxation response within the first 24 hours or between days one and 14 after first dose.

Effect on analgesia

The authors stated there was no evidence of opioid withdrawal or difference in pain experienced between the comparisons. There was no full data, including pre‐cross‐over results provided. We judged the quality of evidence for effect on analgesia to be very low. We downgraded by three levels. This was because evidence is from one study with small sample size, the study was of cross‐over design with no washout between drug cross‐over, and because of unclear risk of bias (reporting bias).

Serious adverse events

There were no serious adverse events.

Number and type of adverse events

The trial did not provide the overall number of adverse events experienced by the participants.

Secondary outcomes

Number of participants who dropped out due to adverse events

Four participants withdrew from the trial. One participant withdrew because of severe diarrhoea caused by the lactulose taken as part of the test on bowel function, one participant because of general deterioration in health while taking naloxone (although not thought to be a causal relationship), one participant because of diarrhoea experienced while receiving the placebo, and one participant withdrew because of nausea after two doses of naloxone at the 10% level (5 mg in this case).

Other measures of laxation response

On the second day following treatment the trial measured small bowel transit times (SBTTs). This was by lactulose‐hydrogen breath tests to detect the release of hydrogen resulting from breakdown of lactulose by colonic bacteria. They found no clear difference in SBTTs between naloxone and placebo groups. The investigators did not provide full data, including pre‐cross‐over results. They used no other measures of laxation response

Relief of other constipation‐associated symptoms

The trial did not report other constipation‐associated symptoms.

Use of rescue medication for laxation

The trial did not report use of rescue medication for laxation.

Quality of life, participant satisfaction with bowel movements, and participant preference

The trial did not report quality of life, participant satisfaction with bowel movements, and participant preference.

Oxycodone/naloxone prolonged‐release tablets versus oxycodone prolonged‐release tablets

Two trials of 231 participants with cancer evaluated oxycodone/naloxone prolonged‐release tablets (OXN PR) compared with oxycodone prolonged‐release (OXY PR) tablets (Ahmedzai 2012; Dupoiron 2017).

One trial of 185 participants with cancer of any stage evaluated the effectiveness of four weeks of treatment (Ahmedzai 2012). The drug dose in both trials arms was 120 mg daily. In addition to the published trial paper we also reviewed FDA and EMA drug reports; these documents did not add any additional data (for references to these reports see Ahmedzai 2012). The other trial evaluated the effectiveness of five weeks of treatment in a general population. We included the trial's subset data on the 46 people with cancer (Dupoiron 2017). The dose of oxycodone/naloxone was up to daily maximum oxycodone 160 mg/naloxone 80 mg.

Overall, we rated the quality of the evidence on effect on analgesia and adverse events as moderate (effect on laxation not reported) (Table 4).

Primary outcomes

Laxation response

The trials did not report laxation response within the first 24 hours and between days one and 14 after first dose.

Effect on analgesia

In one trial using the Brief Pain Inventory‐Short Form at four weeks of treatment, pain scores were similar between the trial arms (OXN PR: mean 3.50, SD 1.88; OXY PR: mean 3.52, SD 1.80) (Ahmedzai 2012). In the other trial, pain scores remained at a low level throughout the study and were comparable between groups (Dupoiron 2017). Neither trial provided full data. We judged the quality of evidence on effect on analgesia in regards to pain intensity as moderate. We downgraded the quality of the evidence by one level because of study limitations (unclear risk of reporting bias).

Serious adverse events

In one trial 18 participants died during the trial, nine in each trial arm (Ahmedzai 2012), in the other trial one person died in the OXN PR arm and three in the OXY PR arm (Dupoiron 2017). None of the deaths were attributed to the trial drugs.

In one trial, there were 12 serious adverse events attributed to the study medication, eight in the OXN PR arm and four in the OXY PR arm (Ahmedzai 2012). There was no clear difference between trial arms in proportion of participants experiencing a serious adverse event (RR 2.00, 95% CI 0.62 to 6.41). The authors did not describe what these events were. In the other trial, there were three serious adverse events in the OXN PR arm and five in the OXY PR arm (Dupoiron 2017). None were attributed to the study medication.

We judged the quality of evidence for serious adverse events to be low. We downgraded the quality of evidence by one level because of study limitations (unclear risk of bias (reporting bias)) and one level for imprecision because of wide CIs.

Number and type of adverse events

In combined analysis of the two trials (234 participants), there was no clear difference between OXN PR in comparison with OXY PR in the proportion of particants experiencing an adverse event (RR 1.08; 95% CO 0.94 to 1.24]. I² = 0%; Analysis 4.1).

4.1. Analysis.

Open in a new tab

Comparison 4 Oxycodone/naloxone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 1 Adverse events.

In both trials, a common adverse event was gastrointestinal symptoms. In one study, there was no clear difference in the number of such events per trial arm (RR 1.21, 95% CI 0.81 to 1.83) (Ahmedzai 2012); in the other trial, there were two events of gastritis in the OXN PR arm and none in the OXY PR arm (Dupoiron 2017). Also in this trial, there were two events of hypercholesterolaemia and hypertriglyceridaemia in the OXN PR arm and none in the other arm (Dupoiron 2017).

We judged the quality of evidence for number of adverse events to be moderate. We downgraded the quality of evidence by one level because of study limitations (unclear risk of bias (reporting bias).

Secondary outcomes

Number of participants who dropped out due to adverse events

There was no clear difference in the proportion of participants who dropped out of the trial in the OXN PR arm compared to the OXY PR arm (20/92 with OXN PR versus 12/92 OXY PR; RR 1.67, 95% CI 0.87 to 3.21) (Ahmedzai 2012). The other trial did not report the number who dropped out due to adverse events in the subset of people with cancer (Dupoiron 2017).

Other measures of laxation response

One trial measured laxation responses from baseline to four weeks (Ahmedzai 2012). In the assessment using the BFI‐Short Form, the trial reported no significant difference in changes between the trial arms in bowel function (MD ‐0.02, 95% CI ‐0.65 to 0.61). Using the PAC‐SYM on participants' assessment of bowel symptoms there was a difference between the trial arms favouring intervention group in total symptom score (MD ‐5.10, 95% CI ‐8.08 to ‐2.12), and in frequency of symptoms (MD ‐0.56, 95% CI ‐0.94 to ‐0.18). The trial did not report per arm the proportion of participants who had a laxation at each of the time points over the four weeks.

Laxation response was the primary outcome in one trial at five weeks (Dupoiron 2017). At this time point, the researchers found a clinically meaningful and treatment difference in BFI in favour of OXN PR arm (14.0, SD 8.1; P = 0.047; full data not provided).

Neither trial reported other measures of laxation response.

Relief of other constipation‐associated symptoms

One study assessed constipation‐associated symptoms using the PAC‐SYM scale, which primarily focuses on bowel‐related symptoms in addition to those of bloat, stomach cramps, and abdominal pain. However, only the total symptom score was provided (Ahmedzai 2012). Therefore, neither trial reported useful data on relief of other constipation‐associated symptoms.

Use of rescue medication for laxation

The use of laxatives (oral bisacodyl) at the end of follow‐up was not significantly different between the trial arms (MD ‐6.59, 95% CI ‐16.61 to 3.43) (Ahmedzai 2012). The authors reported the need for rescue medication was "generally low"' in both treatment groups; they reported in terms of frequency and dose that the difference in use was not significantly different. At the end of follow‐up in the other trial, the mean daily doses of rescue medication in the OXN PR arm was 0.6 (SD 1.1) and in the OXY PR arm 1.4 (SD 2.3) (Dupoiron 2017).

Quality of life, participant satisfaction with bowel movements, and participant preference

One trial used two measures to assess quality of life; the European QoL EQ‐5D instrument and the European Organization for Research and Treatment of Cancer QoL Questionnaire‐Core 30 (EORTC QLQ‐C30) (Ahmedzai 2012). Using the EQ‐5D they found no clear difference between the trial arms (MD 0.01, 95% CI ‐0.11 to 0.13). They did not provide full results at follow‐up for the EORTC QLQ‐C30 scale. The trial did not assess overall satisfaction and participant preference. The other trial did not measure any of these outcomes (Dupoiron 2017).

Methylnaltrexone

Three trials of 518 participants with advanced disease evaluated the effectiveness of subcutaneous methylnaltrexone compared to placebo (Bull 2015; Slatkin 2009; Thomas 2008). In addition to the three published trial papers, we also reviewed FDA and EMA drug reports, which did not identify any additional data (for references to these see Slatkin 2009).

One trial involved a single dose of either methylnaltrexone 0.15 mg/kg or 0.30 mg/kg (Slatkin 2009). The other two trials administered methylnaltrexone every other day for two weeks. One trial administered methylnaltrexone 0.15 mg/kg of bodyweight (Thomas 2008), and the other trial, with the aim of improving ease of administration, administered methylnaltrexone 8 mg to participants whose bodyweight was between 38 kg and 62 kg, or methylnaltrexone 12 mg if they weighed more than 62 kg (Bull 2015). Overall, we rated the quality of the evidence on laxation, effect on analgesia, and adverse events as moderate. See Table 5.

Primary outcomes

Laxation response

In combined analysis of two trials (287 participants), there was a clear difference favouring methylnaltrexone in comparison with placebo in rescue‐free laxation within 24 hours of the first dose (RR 2.77, 95% CI 1.91 to 4.04. I² = 0%; Analysis 1.1) (Slatkin 2009; Thomas 2008). The NNTB was 3 (95% CI 2 to 3). The proportion of participants who had a rescue‐free laxation response with methylnaltrexone within 24 hours of the first dose of treatment was 59.1% and in the placebo arm was 19.5%. We judged the quality of evidence for laxation within 24 hours of the first dose to be moderate. We downgraded by one level for study limitations (unclear risk of bias (reporting bias)).

1.1. Analysis.

Open in a new tab

Comparison 1 Methylnatrexone versus placebo: rescue‐free laxation:, Outcome 1 Within 24 hours of dose.

Two trials measured the laxation response over two weeks (305 participants) (Bull 2015; Thomas 2008). In combined analysis, more participants in the methylnaltrexone group compared to participants in the placebo group had a rescue‐free laxation within four hours of at least four of the maximum seven doses (RR 9.98, 95% CI 4.96 to 20.09. I² = 0%; Analysis 1.2) (Bull 2015; Thomas 2008). The NNTB was 2 (95% CI 2 to 2). The proportion of participants who had a rescue‐free laxation response with methylnaltrexone (within four hours of at least four of the maximum seven doses) was 52.6% and in the placebo arm was 5.3%. We judged the quality of evidence for laxation response over two weeks to be moderate. We downgraded by one level for study limitations (unclear risk of bias (reporting bias)). As the effect size was large, we did not downgrade for imprecision because of wide CIs.

1.2. Analysis.

Open in a new tab

Comparison 1 Methylnatrexone versus placebo: rescue‐free laxation:, Outcome 2 Within 4 hours after 4 of the 7 doses.

Effect on analgesia

Two trials assessed opioid withdrawal symptoms (Slatkin 2009; Thomas 2008). In one trial, they stated that the median change from baseline to day two in score using the Himmelsbach Opioid Withdrawal Scale in both trials arms was 0 (Slatkin 2009). In the other trial at day one and 14, there was no clear difference between the trial arms (day one: MD 0.00, 95% CI ‐0.46 to 0.46; day 14: MD 0.10, 95% CI ‐0.63 to 0.83). We judged the quality of evidence for effect on analgesia in regards to opioid withdrawal to be moderate. We downgraded the quality of evidence by one level for study limitations because of unclear risk of bias (reporting bias).

In one trial, there was a reduction from baseline to four‐hour follow‐up in pain intensity in the methylnaltrexone 0.15 mg/kg group compared to placebo, but not in the methylnaltrexone 0.3 mg/kg group compared to placebo (0.15 mg/kg: MD ‐0.76, 95% CI ‐1.47 to ‐0.05; 0.3 mg/kg: MD ‐0.25, 95% CI ‐0.91 to 0.41) (Slatkin 2009). In the other two trials, participants had similar pain scores in both trial arms at follow‐up (Bull 2015; Thomas 2008). The dose of methylnaltrexone in the trial by Thomas 2008 was 0.15 mg/kg and by Bull 2015 was either 8 mg or 12 mg dependent on participant's bodyweight. In the trial by Thomas 2008, there was no clear difference in score between the trial arms at day one and day 14 (day one: MD 0.20, 95% CI ‐0.62 to 1.02; day 14: MD ‐0.70, 95% CI ‐1.52 to 0.12). The other trial did not provide full data (Bull 2015). We judged the quality of evidence for effect on analgesia in regards to pain intensity to be low. We downgraded the quality of evidence by two levels, one for study limitations (unclear risk of bias (reporting bias)), and one for inconsistency because of differing estimates of effect.

Serious adverse events

In combined analysis of two trials, with 364 participants, the proportion of participants experiencing a serious adverse event was lower in the methylnaltrexone arm (25/179 in methylnaltrexone arm versus 44/185 in placebo arm; RR 0.59, 95% CI 0.38 to 0.93; I² = 0%; Analysis 2.1) (Bull 2015; Thomas 2008). In Thomas 2008, the type of serious adverse events in the 11 participants who were receiving methylnaltrexone were: aneurysm ruptured, respiratory arrest, exacerbation of dyspnoea, suicidal ideation, aggression, malignant neoplasm progression, concomitant disease progression, myocardial ischaemia, aggravation of coronary artery disease, and aggravation of congestive heart failure. Bull 2015 did not describe the types of serious adverse events. In both trials, the investigators considered all serious adverse events as either not related or unlikely to be related to the trial drug. One trial did not report serious adverse events occurring during the randomised phase (Slatkin 2009), although during the open‐label phase three participants experienced such an event. One participant had flushing, one participant had delirium possibly related to methylnaltrexone, and one participant had severe diarrhoea and subsequent dehydration and cardiovascular collapse considered to be related to methylnaltrexone. We judged the quality of evidence for risk of a serious adverse event to be moderate. We downgraded the quality of evidence by one level for study limitations. This was because of unclear risk of bias (reporting bias).

2.1. Analysis.

Open in a new tab

Comparison 2 Methylnaltrexone versus placebo: serious adverse event, Outcome 1 Serious adverse event.

Number and type of adverse events

In combined analysis of the three trials, with 518 participants, the proportion of participants experiencing adverse events was not clearly different between the trial arms (RR 1.17, 95% CI 0.94 to 1.45; random‐effects model; I² = 74% suggesting substantial heterogeneity between trials; Analysis 3.1) (Bull 2015; Slatkin 2009; Thomas 2008). We considered subgroup and sensitivity analyses to explain the heterogeneity. Sensitivity analysis demonstrated that the primary meta‐analysis was robust. Omitting the trial at high risk of bias because of small sample size (Slatkin 2009) resulted in a smaller estimate of effect. It did not change the overall result or conclusions. See Table 8. We judged the quality of evidence for adverse events to be low. It was downgraded by two levels; one for study limitations (unclear risk of reporting bias) and one because of inconsistency due to substantial statistical heterogeneity between the trials, this was upgraded since sensitivity analysis accounted for heterogeneity.

3.1. Analysis.

Open in a new tab

Comparison 3 Methylnaltrexone versus placebo: adverse event, Outcome 1 Adverse events.

2. Sensitivity analyses.

Methylnaltrexone vs placebo^a
AEs	RR 1.07, 95% CI 0.96 to 1.19
AE of abdominal pain	RR 2.15, 95% CI 1.28 to 3.62
AE of nausea	RR 0.87, 95% CI 0.46 to 1.65
AE of vomiting	RR 0.70, 95% CI 0.33 to 1.47

Open in a new tab

^aomitting trial of high risk of bias.

AE: adverse event; CI: confidence intervals; RR: risk ratio.

Two of the trials reported some of the adverse events as severe (Slatkin 2009; Thomas 2008). One reported that 19/102 participants experienced a severe adverse event that was possibly related to the intervention drug; most commonly this event was abdominal pain (Slatkin 2009). The other trial did not describe what the events were and whether they were considered related to methylnaltrexone, but more participants in the placebo group experienced severe adverse events than in the intervention group (5/63 (8%) with methylnaltrexone versus 9/71 (13%) with placebo).

All three trials reported that participants in both trial arms experienced abdominal pain, flatulence, nausea, and vomiting (Bull 2015; Slatkin 2009; Thomas 2008). In combined analysis, participants in the intervention arm compared to participants in the placebo arm were more likely to experience abdominal pain (RR 2.39, 95% CI 1.07 to 5.34; random‐effects model; I² = 65% suggesting substantial heterogeneity between trials). Likewise, in combined analysis participants in the intervention arm compared to participants in the placebo arm were more likely to experience flatulence (RR 2.09, 95% CI 1.07 to 4.08; I² = 0%). In combined analyses, there was no clear difference between the trial arms in the proportion who experienced nausea (RR 0.97, 95% CI 0.89 to 1.06; random‐effects model; I² = 63% suggesting substantial heterogeneity between trials) or vomiting (RR 0.99, 95% CI 0.92 to 1.08; random‐effects model; I² = 67% suggesting substantial heterogeneity between trials). Sensitivity analyses demonstrated that the primary meta‐analyses were robust with regards to risk of experiencing abdominal pain, nausea, and vomiting. Omitting the trial at high risk of bias because of small sample size resulted in a smaller estimate of effect (Slatkin 2009). It did not change the overall result or conclusions. See Table 8.

Two trials also reported that participants experienced diarrhoea (Bull 2015; Thomas 2008), dizziness (Slatkin 2009; Thomas 2008), peripheral oedema (Bull 2015; Thomas 2008), and restlessness (Slatkin 2009; Thomas 2008). In combined analysis, there was no clear difference between trials in the proportion of participants experiencing these adverse events. See Table 9. Two trials also reported on falls (Bull 2015; Thomas 2008), and somnolence (Slatkin 2009; Thomas 2008). For these adverse events in combined analysis, there was also no significant difference between trial arms. See Table 9.

3. Types of adverse event: reported in more than one trial of methylnaltrexone (versus placebo).

Adverse event	RR (95% CI)	I²statistic on heterogeneity
Abdominal pain	2.39 (1.07 to 5.34)	65%
Diarrhoea	1.02 (0.93 to 1.11)	51%
Dizziness	4.09 (0.99 to 16.83)	0%
Falls	1.02 (0.89 to 1.16)	84%
Flatulence	2.09 (1.07 to 4.08)	0%
Nausea	0.97 (0.89 to 1.06)	63%
Peripheral oedema	1.01 (0.50 to 2.03)	0%
Restlessness	0.83 (0.32 to 2.12)	0%
Somnolence	1.00 (0.93 to 1.08)	73%
Vomiting	0.99 (0.92 to 1.08)	67%

Open in a new tab

CI: confidence interval; RR: risk ratio.

Only one trial reported other adverse events. See Table 10 for the proportion of participants per trial and per arm that reported these events.

4. Types of adverse events: reported in only one trial of methylnaltrexone.

Adverse event	Methylnaltrexone (%)	Placebo (%)
Abdominal distension^a	1 (2)	6 (8)
Abdominal tenderness^a	1 (2)	4 (6)
Asthenia^a	4 (6)	4 (6)
Anxiety^b	5 (4.9)	0 (0)
Arthralgia^b	3 (2.9)	1 (1.9)
Back pain^c	9 (7.8)	3 (2.9)
Confusional state^c	7 (6.0)	9 (7.9)
Dehydration^a	2 (3)	4 (6)
Fatigue^b	4 (3.9)	1 (1.9)
Hypotension^a	0 (0)	4 (6)
Increased body temperature^a	5 (8)	2 (3)
Lethergy^a	4 (6)	4 (6)
Malignant‐neoplasm progression^a	7 (11)	9 (13)
Pain exacerbation^b	8 (8)	2 (4)
Rhinorrhoea^b	6 (5.9)	1 (1)
Sweating increased^b	8 (7.8)	4 (7.7)
Tachycardia^a	1 (1)	4 (6)

Open in a new tab

^aReported in trial by Thomas 2008.

^bReported in trial by Slatkin 2009.

^cReported in trial by Bull 2015.

Secondary outcomes

Number of participants who dropped out due to adverse events

Two trials reported that there were dropouts due to adverse events. In combined analysis, there was no significant difference in the proportion of participants who dropped out between the trial arms (RR 1.22, 95% CI 0.54 to 2.76; I² = 0%; Analysis 3.2) (Bull 2015; Thomas 2008). The other trial reported no dropouts due to adverse events.

3.2. Analysis.

Open in a new tab

Comparison 3 Methylnaltrexone versus placebo: adverse event, Outcome 2 Dropouts due to adverse event.

Other measures of laxation response

In both trials of two‐week treatments there was a shorter time to laxation in the methylnaltrexone group that persisted for each of the seven treatment doses (for all comparisons: P < 0.005 (Bull 2015); P < 0.002 (Thomas 2008)). In combined analysis of all three trials, there was a difference favouring methylnaltrexone in comparison with placebo in rescue‐free laxation within four hours of the first dose (placebo or methylnaltrexone) (RR 3.87, 95% CI 2.83 to 5.28; I² = 0%; Analysis 1.3) (Bull 2015; Slatkin 2009; Thomas 2008). The proportion of participants in total who had a laxation response within four hours of the first (or second) dose of treatment ranged from 61.4% in the methylnaltrexone groups and 16.0% in the placebo groups. The single‐dose trial using the GCIC found that the proportion of participants who reported an improvement in constipation distress at four hours significantly favoured the methylnaltrexone arm (irrespective of dose) compared to placebo (RR 1.84, 95% CI 1.23 to 2.75) (Slatkin 2009). The trial by Bull 2015 measured the mean number of rescue‐free laxation responses within 24 hours after dosing in the first and second week: at both time points participants receiving methylnaltrexone had significantly more laxations than participants receiving placebo (first week: MD 1.90, 95% CI 0.55 to 3.25; second week: MD 1.20, 95% CI 0.15 to 2.25).

1.3. Analysis.

Open in a new tab

Comparison 1 Methylnatrexone versus placebo: rescue‐free laxation:, Outcome 3 Within 4 hours of first dose.

Two trials reported clinician ratings of bowel status using the GCIC ratings were assessed in two trials (287 participants) (Slatkin 2009; Thomas 2008). In combined analysis, clinician ratings that bowel status had improved at week one were greater in those in the interventions groups (RR 2.37, 95% CI 1.66 to 3.38; I² = 25%; Analysis 1.7).

1.7. Analysis.

Open in a new tab

Comparison 1 Methylnatrexone versus placebo: rescue‐free laxation:, Outcome 7 Clinician global impression of improvement in bowel status at 1 week.

All three trials reported that time to first rescue‐free laxation favoured methylnaltrexone (median times in the intervention group versus placebo: 0.8 hours versus 23.6 hours (Bull 2015), 1.1 hours versus > 24 hours (Slatkin 2009), 6.3 hours versus > 48 hours (Thomas 2008)).

Relief of other constipation‐associated symptoms

None of the trials measured the relief of other constipation‐associated symptoms such as bloating, abdominal distention, gastric reflux, abdominal cramping, dry mouth, epigastric fullness, nausea, and vomiting, although some of these symptoms were reported as adverse events.

Use of rescue medication for laxation

Two trials recorded the need for rescue laxatives. In both trials, more participants in the placebo group needed rescue laxatives than participants in the intervention groups.

In one trial, fewer participants used rescue laxatives in the methylnaltrexone group than in the placebo group (31/116 with methylnaltrexone versus 46/114 with placebo; RR 0.66, 95% CI 0.46 to 0.96) (Bull 2015). It was also recorded in the FDA report on the trial by Thomas 2008 that there was an increased use in enemas in both trial arms. This was greater in the placebo group (23.8% with methylnaltrexone versus 35.2% with placebo).

Quality of life, overall satisfaction with bowel movements, and participant preference

None of the trials measured quality of life or participant preference. Two trials (287 participants) assessed participant ratings of bowel status using the GCIC ratings (Slatkin 2009; Thomas 2008). In combined analysis, participant ratings that bowel status had improved at one week were significantly greater in the methylnaltrexone groups (RR 2.32, 95% CI 1.64 to 3.27; I² = 0%; Analysis 1.6). Both trials measured constipation distress at day one (RR 1.87, 95% CI 1.34 to 2.59; I² = 25%).

1.6. Analysis.

Open in a new tab

Comparison 1 Methylnatrexone versus placebo: rescue‐free laxation:, Outcome 6 Participant global impression of improvement in bowel status at 1 week.

Methylnaltrexone dose response

Two trials with 135 participants with advanced disease evaluated different dosing regimens of methylnaltrexone (Portenoy 2008; Slatkin 2009). One trial, irrespective of bodyweight, explored fixed doses of methylnaltrexone 1 mg, 5 mg, 12.5 mg, or 20 mg in 33 participants (Portenoy 2008). Because of the limited number of participants in the trials, we provided outcomes for participants taking 1 mg compared to participants of 5 mg or greater. The drug was administered on alternate days over one week. The other trial compared one dose on different dose‐ranging schedules of 0.15 mg/kg for 47 participants with 0.3 mg/kg for 55 participants (Slatkin 2009). We did not consider combining the data because the dosing schedules differed. Overall, we rated the quality of evidence on laxation, effect on analgesia, and adverse events to be low. See Table 6.

Primary outcomes

Laxation response

Both trials measured laxation response within 24 hours of the first dose of methylnaltrexone. There was no clear difference between participants taking a higher dose to participants on a lower dose (RR 0.82, 95% CI 0.41 to 1.66 (Portenoy 2008); RR 1.07, 95% CI 0.81 to 1.42 (Slatkin 2009)). We judged the quality of evidence for laxation response within 24 hours as low. We downgraded the quality of evidence by two levels, because of study limitations. This was because of unclear risk of bias (reporting bias) and small sample sizes (high risk of bias).

One trial reported outcomes after dosing at day three and five (Portenoy 2008). Laxation response within 24 hours did not clearly differ in participants receiving 1 mg compared to participants receiving 5 mg or greater on day three or on day five (day three: RR 0.47, 95% CI 0.18 to 1.25; day five: RR 0.21, 95% CI 0.03 to 1.31). The other trial did not measure response beyond one day (Slatkin 2009). We judged the quality of evidence for laxation response at day three and five to be low. We downgraded the quality of evidence by two levels for study limitations. This was because of unclear risk of bias (reporting bias) and results from a single study with a small sample size (high risk of bias).

Effect on analgesia

In both trials, pain intensity did not change from baseline and was similar in both trial arms receiving the different doses of methylnaltrexone (Portenoy 2008; Slatkin 2009). In one trial, the mean change in pain from baseline to four‐hour evaluation was not clearly different (MD ‐0.51, 95% CI ‐1.49 to 0.47) (Slatkin 2009); the other trial did not provide full results. Both trials reported that the use of methylnaltrexone did not result in opioid withdrawal (Portenoy 2008; Slatkin 2009). In one trial, there was a no clear difference in the mean change from baseline to four‐hour evaluation (MD ‐0.04, 95% CI ‐0.73 to 0.65) (Slatkin 2009); the other trial did not provide full results. We judged the quality of evidence for effect on analgesia to be low. We downgraded the quality of evidence by two levels for study limitations. This was because of unclear risk of bias (reporting bias) and small sample sizes (high risk of bias).

Serious adverse events

In one trial, 15 participants experienced a serious adverse event; however, risk of serious adverse events were not reported per trial arm (Portenoy 2008). The events were lymphadenectomy, febrile neutropenia, depressed level of consciousness, suicide attempt, and delirium. All were considered unrelated to study medication. In the other trial, no serious adverse events occurred during the randomised trial phase, although during the open‐label phase three participants experienced such an event of which one had severe diarrhoea and subsequent dehydration and cardiovascular collapse (Slatkin 2009). These were considered to be related to the drug. We did not judge the quality of evidence for serious adverse events as they did not report incidence per trial arm.

Number and type of adverse events

In the fixed‐dose trial, all participants experienced an adverse event (Portenoy 2008). In the other trial, there was no clear difference in dose arms in the occurrence of an adverse event (RR 0.90, 95% CI 0.73 to 1.13) (Slatkin 2009). The most common adverse event in both trials and per trial arm was abdominal pain. We judged the quality of evidence for adverse events to be low. We downgraded the quality of evidence by two levels for study limitations because of unclear risk of bias (reporting bias) and small sample size (high risk of bias).

Secondary outcomes

Number of participants who dropped out due to adverse events

In one trial, one participant discontinued the trial (during the double‐blind treatment phase) because of an adverse event (Portenoy 2008). This was an 84‐year old man who withdrew due to syncope (taking methylnaltrexone 12.5 mg). The event was transient and resolved without sequelae; the investigators assessed that it was related to the medication. This trial also reported that in the open‐label phase, after receiving three doses, a 20‐year old man was withdrawn from the trial due to abdominal cramping that was considered as probably related to the trial medication. In the other trial, none of the participants discontinued because of an adverse event (Slatkin 2009).

Other measures of laxation response

In the single‐dose trial of 154 participants there was no clear difference in the proportion of participants who had a rescue‐free laxation within four hours of receiving methylnaltrexone between participants in the trial arm who received 0.15 mg/kg with participants who received 0.3 mg/kg (RR 1.06, 95% CI 0.77 to 1.46) (Slatkin 2009). In this trial, the proportion of participants who reported an improvement in constipation distress within four hours was similar (30/47 (64.4%) with methylnaltrexone 0.15 mg/kg versus 35/55 (63.5%) with methylnaltrexone 0.3 mg/kg), as was global improvement (27/47 (58.7%) with methylnaltrexone 0.15 mg/kg versus 32/55 (58.8%) with methylnaltrexone 0.3 mg/kg). In the fixed dose trial, 10% (1/10) of participants taking methylnaltrexone 1 mg had a laxation within four hours compared to 43% (3/7) taking methylnaltrexone 5 mg, 60% (6/10) taking methylnaltrexone 12.5 mg, and 33% (2/6) taking methylnaltrexone 20 mg (Portenoy 2008). Laxation response within four hours did not significantly differ in participants receiving 1 mg compared to participants receiving 5 mg or greater (RR 0.21, 95% CI 0.03 to 1.41).

One trial reported outcomes at four hours after dosing at day three and five (Portenoy 2008). Laxation response within four hours did not significantly differ in participants receiving 1 mg compared to participants receiving 5 mg or greater on day three or day five (day three: RR 0.34, 95% CI 0.10 to 1.22; day five: RR 0.09, 95% CI 0.01 to 1.38).

In one trial, the median time to rescue‐free laxation was 1.10 hours in the methylnaltrexone 0.15 mg/kg group and 0.8 hours in the methylnaltrexone 0.3 mg/kg group (Slatkin 2009). In the other trial, for the lowest dose of 1 mg it was more than 48 hours whereas for the higher doses the first laxation was at 1.72 with methylnaltrexone 5 mg, 0.48 with methylnaltrexone 12.5 mg, and 6.75 hours with methylnaltrexone 20 mg (Portenoy 2008).

One of the two‐week trials reported that there was a similar proportion of watery bowel movements in the methylnaltrexone arm compared with the placebo arm (16% (after 28 of 176 drug trial doses) with methylnaltrexone) versus 17% (after 8 out of 48 doses) with placebo) (Thomas 2008). In the single dose trial in participants who had a laxation within four hours of dosing, eight out of the 29 receiving methylnaltrexone had at least one watery laxation compared to none of the seven participants receiving placebo (Slatkin 2009).

Two trials (287 participants) measured self‐report of constipation distress (Slatkin 2009; Thomas 2008). In both trials, distress was reduced more at 24 hours in the methylnaltrexone group than in placebo group (combined analysis: RR 1.87, 95% CI 1.34 to 2.59; I² = 0%; Analysis 1.5).

1.5. Analysis.

Open in a new tab

Comparison 1 Methylnatrexone versus placebo: rescue‐free laxation:, Outcome 5 Improvement in constipation distress at day 1.

One trial reported bowel status using the Clinical Global Impression of Change (Slatkin 2009). There was improvement at the end of the double‐blind phase for methylnaltrexone 0.15 mg/kg (58.7%) and methylnaltrexone 0.3 mg/kg (58.8%).

Relief of other constipation‐associated symptoms

None of the trials measured the relief of other constipation‐associated symptoms, although some of these symptoms, such as abdominal pain and nausea, were recorded as adverse events.

Use of rescue medication for laxation

One trial reported that participants in the trial arm receiving the lowest dose (methylnaltrexone 1 mg) required a rescue laxative approximately twice as often as those in the higher dose groups (Portenoy 2008). The other trial did not compare use of rescue medication (Slatkin 2009).

Quality of life, satisfaction with bowel movements, and participant preference

None of the trials assessed the impact of treatment on quality of life or participant preference (Slatkin 2009; Thomas 2008). One trial assessed participants' level of satisfaction with the trial medication using a 7‐point scale (Portenoy 2008). They did not report the level of satisfaction but reported no difference in satisfaction between the trial arms.

Discussion

Summary of main results

This review update sought to establish the effectiveness and safety of MOAs for OIBD in people with cancer and people receiving palliative care. Three of the eight RCTs explored outcomes in cancer populations irrespective of disease stage; one compared oral naldemedine to placebo, two compared oral prolonged released oxycodone/naloxone with oxycodone alone. Oral naloxone only compared to placebo was evaluated in people with advanced cancer. The other four trials compared either subcutaneous methylnaltrexone with placebo or different regimens of methylnaltrexone in palliative care populations in which the majority of participants had advanced cancer. All evaluated the effect of MOAs in populations where all or over 90% were on regular regimens of laxatives. Four trials were at a high risk of bias because of small sample sizes (fewer than 50 participants per trial arm), all were at an unclear risk of selection bias as they under reported allocation concealment or random sequence generation (or both), and seven were at an unclear risk of reporting bias as they did not provide a protocol. Data for all our primary outcomes of interest were only provided for methylnaltrexone compared to placebo. In one trial, only a subset of the sample was eligible for this review. We used the GRADE quality of evidence to assess primary outcomes. Our GRADE judgements differed by trial intervention; overall, it was moderate for naldemedine and methylnaltrexone. For naloxone as an adjunct, it was moderate, and naloxone taken on its own was very low. However, these judgements for naloxone were only for the effect on analgesia and adverse events, not laxation for which there were no data.

For naldemedine, we found moderate‐quality evidence that the drug clearly increased the number of spontaneous laxations over two weeks in people with cancer. There was also a dose response relationship identified with higher doses clearly increasing during this time the number of spontaneous laxations (moderate‐quality evidence). The higher doses were 0.2 mg and 0.4 mg daily compared with the dose of 0.1 mg daily. Evidence that naldemedine had no impact on analgesia in regards to opioid withdrawal symptoms was of moderate quality. There were five serious adverse events that occurred in participants taking naldemedine and none in the placebo group. We judged this as low‐quality evidence. We judged the quality of evidence that there was an increase in adverse events to be moderate. The most common adverse event was diarrhoea.

Evidence on naloxone was limited. Neither the trial of naloxone alone in people with advanced cancer or the two evaluating it in combination with oxycodone in people with cancer evaluated laxation response at 24 hours or over two weeks, and, for some evaluations (e.g. effect on analgesia), the studies did not provide full data. The trial of naloxone alone did not report adverse events.

There was moderate evidence from combined analysis that in people receiving palliative care methylnaltrexone improved laxation, with up to 59.1% of participants having a laxation within 24 hours of the first dose whereas in the placebo group it was up to 19.5% (RR 2.77, 95% CI 1.91 to 4.04; NNTB 3, 95% CI 2 to 3). One trial clearly demonstrated that fewer participants in the methylnaltrexone arm required rescue laxatives compared to placebo. There was also moderate evidence from a combined analysis on laxation response over two weeks, with up to 52.6% of participants having a rescue‐free laxation response (within four hours of at least four of the maximum seven doses), whereas in the placebo group it was up to 5.3% (RR 9.98, 95% CI 4.96 to 20.09; NNTB 2 (95% CI 2 to 3). We judged the evidence of the impact of methylnaltrexone on analgesia in regards to opioid withdrawal symptoms to be moderate and in regards to pain intensity to be low. There was moderate‐quality evidence that the drug did not increase the risk of a serious adverse event. There was low‐quality evidence that methylnaltrexone increased the risk of adverse events in regards to abdominal pain and flatulence. None of the adverse events were severe. However, in one trial, in a subsequent open‐study phase (when both the researchers and participants knew which treatment was being administered), one participant experienced severe diarrhoea and subsequent dehydration and cardiovascular collapse considered related to the drug.

We found low‐quality evidence that there was no impact of different doses of methylnaltrexone on laxation response, on pain analgesia, or adverse events. We were unable to judge the quality on risk of serious adverse events. However, it is important to highlight that during one of the trials, 15 participants experienced a serious adverse event. The investigators did not provide details on what the events were, or whether they were considered to be related to the trial drug. All participants experienced an adverse event in this trial.

Overall completeness and applicability of evidence

We sought trial evidence widely beyond published papers. Where available, we obtained regulatory documents; although these provided few new data.

Our review findings were limited. The trials were few and this limited our combined analyses. In some analyses, there was statistical heterogeneity across the trials. This related to adverse effects of methylnaltrexone in comparison to placebo. Sensitivity analyses demonstrated that the primary meta‐analyses were robust with regards to the risk of overall adverse events, and individual adverse events of abdominal pain, nausea, and vomiting. Omitting the trial at high risk of bias because of small sample size (Slatkin 2009) resulted in all analyses with a smaller estimate of effect but it did not change the direction of effect.

The evidence on naldemedine was only from one trial. We are aware of at least one other trial completed but not published in full; when it becomes available the evidence from this trial may inform better the evidence on this drug.

In the naloxone trials, not all our primary outcomes of interest were the focus of the research. The trial on naloxone only measured one of our three primary outcomes of interest, specifically the effect on analgesia, but not the effect on laxation or adverse events. However, both trials of naloxone in combination with oxycodone did measure laxation at later time points (four and five weeks). Here they found, across the studies, an improvement in bowel function in four out of five assessments.

The body of evidence could be argued as stronger for methylnaltrexone, as it was derived from more studies and with the total number of participants higher than that for trials on other MOAs. It is important to reflect that this is moderate‐quality evidence only, and in one of the four methylnaltrexone trials the assessment of impact of the drug may have been affected as participants in the placebo arm were on higher doses of opioids than those in the methylnaltrexone arm. Our analysis was more limited on methylnaltrexone dose response as we were unable to combine the studies because of different dosing schedules.

Participant outcomes on satisfaction and preference were under evaluated. Only one trial assessed quality of life (Ahmedzai 2012). The trial found no difference in quality of life between participants in the oxycodone/naloxone group and participants in the oxycodone only group. There are also other outcomes that were not measured in any of these trials that earlier research suggests need further exploration. This includes whether MOAs, in particular, methylnaltrexone, increase cancer survival (Janku 2015).

We found no completed trials that fulfilled our inclusion criteria on naloxegol, which in 2014 was approved by the FDA for use in OIBD in people without cancer. However, we are awaiting clarification for one trial from the authors or funders as we are unclear whether it fulfils our inclusion criteria (Webster 2013), and two potentially relevant trials are in progress (NCT02745353; NCT02839889).

Evaluations on the development of new MOAs for OIBD, their effectiveness, and safety is an active research field. We noted 11 trials in populations of people with cancer or people receiving palliative care (or both) that were in progress or were completed but published results were not yet available at the time of publishing this review (Dimitroulis 2014; JAPIC‐CTI‐132340; NCT00135577; NCT00331045/00101998; NCT01438567; NCT02321397; NCT02574819; NCT02745353; NCT02839889; Neefjes 2014; Peppin 2013).

Quality of the evidence

All eight trials were vulnerable to biases. Four were at high risk of bias as they involved a sample of fewer than 50 participants per trial arm. Using the GRADE approach, we assessed the quality of evidence for our primary outcomes of interest.

For both naldemedine and methylnaltrexone, the overall quality of evidence for improving laxation response (in comparison with placebo) was moderate. This means we are moderately confident in the effect estimate and the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. The evidence base to judge quality could be viewed as stronger with methylnaltrexone than naldemedine as it is based on several trials of in total 518 participants, rather than in naldemedine one trial of 225 participants. However, while data from 518 participants in the methylnaltrexone trials was used for adverse event assessments, in comparisons on laxation response data from 287 participants was used.

We judged the quality of evidence that the evaluated MOAs had no impact on the effect of analgesia in regards to naldemedine as moderate (for opioid withdrawal, they did not report pain intensity), in regards to methylnaltrexone low to moderate. The quality of evidence that the MOAs did increase the risk of serious adverse events was low for naldemedine, and moderate for methylnaltrexone. In regards to non‐serious adverse events, there was moderate‐quality evidence that naldemedine increased risk of adverse events and low‐quality evidence that methylnaltrexone did not increase the risk. The overall quality of evidence that there was no difference in our primary outcomes of interest between higher doses compared to lower doses of methylnaltrexone was low. The quality of evidence on naloxone (in comparison with placebo) was very low in regards to no effect on analgesia (adverse events and laxation responses were not reported). The quality of evidence on naloxone in combination with oxycodone was moderate, it had no impact on analgesia or on the risk of adverse events (early laxation responses were not reported).

Potential biases in the review process

We sought trial evidence widely, including five citation databases. We sought unpublished trial data from pharmaceutical and regulatory agencies databases. However, there are limited guidelines in how to seek unpublished data and searching regulatory agency websites is not straightforward.

We limited inclusion to trials that specified that their participants had cancer, or were in palliative care irrespective of disease stage. This is likely to have led to a loss of data, as trials we excluded may have included people with such characteristics, but the trial papers did not provide this 'finer' detail.

We included trials with methodological limitations. In addition, there is a potential problem due to carryover effects in the cross‐over designed trial (Sykes 1996), and our combined analysis was limited by the number of trials available.

Agreements and disagreements with other studies or reviews

This Cochrane systematic review specifically examined the evidence for MOAs for OIBD in cancer and palliative care populations. Our results on methylnaltrexone in palliative care were similar to those in the earlier relevant Cochrane Review that included two of the four trials on methylnaltrexone included in this review (Candy 2011).

There are reviews that have evaluated the effect of MOAs for OIBD in general populations, although no recent (published since 2014) Cochrane Review. One review of a broader population identified 14 trials (Ford 2013). In addition to four of the trials included in this review, they included trials on methadone‐induced constipation and trials involving participants receiving an opioid for chronic non‐malignant pain. In their meta‐analysis of 14 trials of 4101 participants they found the MOAs methylnaltrexone, naloxone, and alvimopan were superior to placebo for the treatment of opioid‐induced constipation. However, the numbers of adverse events were significantly more common. The reviews by Mehta 2016 and Siemens 2015 found positive results on laxation response of methylnaltrexone and other MOAs compared to placebo evaluated in general populations in treating opioid‐induced constipation.

Authors' conclusions

Implications for practice.

For people with cancer and people receiving palliative care with opioid‐induced bowel dysfunction

There is moderate‐quality evidence in participants with cancer that have opioid‐induced bowel dysfunction (OIBD), despite laxative use, that the mu‐opioid antagonist, naldemedine, taken orally may improve bowel function within two weeks of the start of administration. However, in the one trial that assessed naldemedine, there were five serious adverse events that occurred in participants taking naldemedine arm and none in the placebo arm. We judged the trial as providing low‐quality evidence about whether this drug increases the risk of serious adverse events. It is not clear if any of the events were related to the medication. There is moderate‐quality evidence that naldemedine increases the chances of experiencing a non‐serious adverse event. The most common adverse event is diarrhoea.

Trials on effect of naloxone alone or in combination with oxycodone in treating OIBD in people with cancer did not measure bowel function within two weeks of the start of administration. There is very low‐quality evidence to support the suggestion that naloxone alone has no impact on analgesia in people with cancer. For naloxone in combination with oxycodone there is moderate quality evidence to support the suggestion that it has no impact on analgesia and moderate to low quality evidence that it has no effect on risk of adverse events.

There is moderate‐quality evidence in palliative care that when conventional laxatives have failed that the mu‐opioid antagonist, methylnaltrexone, administered subcutaneously, can be successful within 24 hours and over two weeks in improving bowel function. There is low‐quality evidence that it can increase the chances of experiencing abdominal pain and flatulence.

There is low‐ to moderate‐quality evidence that the mu‐opioids antagonists investigated in this review did not reduce the effect of the opioid analgesics. Although for naldemedine this was measured with regards to opioid withdrawal symptoms but not with regards to pain intensity experience. This is distinct from the situation when naloxone is taken on its own, where the evidence on efficacy of opioid analgesics is very low. We found no studies on children.

For clinicians

In this update, there is new moderate‐quality evidence that oral naldemedine in people with cancer may be effective within two weeks of administration in inducing laxation where conventional laxatives have failed. However, in the one trial that assessed naldemedine there were five serious adverse events in participants in the naldemedine arm and no serious adverse events in participants taking placebo. It is not clear if any of the events were related to naldemedine. We judged this as low‐quality evidence on whether this drug increases the risk of serious adverse events. There was also moderate‐quality evidence that naldemedine did increase the chances of experiencing another (non‐serious) adverse event, commonly this was diarrhoea. The conclusions on the effectiveness of subcutaneous methylnaltrexone for OIBD in people receiving palliative care remain unchanged. Where conventional laxatives have failed, there is moderate‐quality evidence that methylnaltrexone is effective in the short‐term (24 hours). Over two weeks, there is low‐quality evidence that it is effective in inducing laxation for a proportion of people in palliative care with OIBD. Methylnaltrexone is associated with an increase in certain adverse events, such as abdominal pain and flatulence. In the three trials comparing methylnaltrexone with placebo, there is no evidence to suggest this medication increases the risk of serious adverse events. However, there were 15 serious adverse events in one of the dose‐response trials, that were not accounted for by the authors.

Trials on naloxone alone or in combination with oxycodone in treating OIBD in people with cancer did not measure all review outcomes of interest, including laxation response within two weeks of drug administration. For naloxone alone there is very low‐quality evidence to support the suggestion that it has no impact on analgesia in people with cancer. For naloxone in combination with oxycodone there is moderate quality evidence to support the suggestion that it has no impact on analgesia and moderate‐ to low‐ quality evidence that it has no effect on risk of adverse events. There is low‐ to moderate‐ quality evidence that the mu‐opioids antagonists investigated in this review did reduce the effect of the opioid analgesics. Although for naldemedine this was measured with regards to opioid withdrawal symptoms and not the pain intensity experience. This is distinct from the situation when naloxone is taken on its own, where the evidence on this outcome was very low. However, all these treatments are unlikely to be effective in all participants and not all outcomes have been fully evaluated, for example, treatment satisfaction and preference. We found no studies on children.

For policy makers

In adults in palliative care, when conventional laxatives have failed, subcutaneous methylnaltrexone within 24 hours and at two weeks, and oral naldemedine at two weeks can be successful in improving bowel function. In adults in palliative care, laxatives are first‐line drug therapy. When conventional laxatives have failed, subcutaneous methylnaltrexone is a second‐line therapy if an immediate response is required. Oral naldemedine is a second‐line therapy if an immediate laxation is not essential.

For funders of the intervention

There is sufficient evidence in palliative care for adults that when conventional laxatives have failed subcutaneous methylnaltrexone can improve bowel function within 24 hours. There is moderate‐quality evidence that in people with cancer oral naldemedine can improve bowel function within two weeks of start of administration. We would encourage funders to consider, when conventional laxatives have failed, subcutaneous methylnaltrexone as a second‐line therapy if an immediate response is required. Oral naldemedine is a second‐line therapy if an immediate laxation is not essential.

Implications for research.

We found 11 ongoing and completed but not published trials. This includes an evaluation of naloxegol. Therefore, some of the suggestions listed in this section may need to be modified once the results of these trials are published.

General

Rigorous randomised controlled trials measuring standardised and clinically and participant relevant outcomes are needed to establish the effectiveness and safety of mu‐opioid antagonists. Trials should be reported according to CONSORT guidelines (Schulz 2010).

Design

Attrition rates in the included trials and the relatively small numbers of eligible participants in any one palliative care treatment unit suggest that any trial of laxative efficacy should involve participants recruited from multiple centres.

Measurement (endpoints)

There is a need to include multiple measures in addition to laxation response, these include analgesia effect, tolerability, quality of life, participant preference, and costs.

Feedback

Feedback on methylnaltrexone in palliative care, March 2011

Summary

After reviewing the Cochrane review (1), our group feels it is important to highlight a few issues around the use of methylnaltrexone for the management of constipation in people receiving palliative care. Some of the comments specifically relate to the original trials by Thomas et al. and Slatkin et al. (2, 3)

1) Factors that could affect overall beneficial treatment effect due to differences at baseline between treatment groups

Although it was noted that the two groups were well balanced at baseline in Thomas 2008, a few parameters were not balanced. For example:

The median dose of opioid was greater, though not statistically significant, in the placebo group (100 mg [10 to 10,160 mg]) compared to methylnaltrexone group (150 mg [9‐4160 mg]), that would give an advantage to the methylnaltrexone arm because it could of lead to more treatment resistant constipation in the placebo group.
Another baseline difference was the primary diagnosis. 20% of patients in the placebo group had "other" as their primary diagnosis compared to 8% in the methylnaltrexone arm. "Other" included diagnosis such as "failure to thrive, amyotrophic lateral sclerosis, end‐stage multiple sclerosis, malabsorption syndrome, pernicious anaemia, rheumatoid arthritis, Buerger's disease, cerebral vascular accident, idiopathic pulmonary fibrosis, peripheral vascular disease, diabetes mellitus, hypoxic brain injury, multiple systems failure, chronic pain or multiple fractures, and end‐stage Parkinson's disease." Most of these "other" diagnosis may further reduce patients' mobility and oral intake leading to treatment resistant constipation. A 12% increase in such diagnosis in the placebo group favours treatment advantage in the methylnaltrexone arm.

Implication – It is possible that these issues can affect the overall treatment effect; however, it would be difficult to assess whether it was overestimated or underestimated.

2) Questionable dosing regimen

In the study by Thomas 2008, the study investigator decided to study regular dosing of methylnaltrexone (at a dose of 0.15 mg per kilogram of body weight) or an equal volume of placebo administered subcutaneously on alternate days for two weeks even after patient had a regular bowel movement. "Would this questionable dosing regimen be followed in regular clinical practice? Would these patients be subjected to unnecessary adverse effects? Of note, both FDA and Health Canada have recently issued warning on rare cases of gastrointestinal perforation with the use of methylnaltrexone. (4, 5)

Implication – Once effective, is there a need to continue regular dosing?

3) Questionable place of therapy

It seems as though the placebo group in Thomas 2008 was at a disadvantage from the start. Patients were constipated on their laxative regimens prior to randomization and were randomized to receive those same regimens plus placebo. A better clinical question would be to compare the effect of methylnaltrexone against other bowel agents. For example: in certain jurisdictions, a step‐wise approach to bowel care is utilized with enema or digital disimpaction being the final step. This might have been a better comparator intervention.

Implication – Methylnaltrexone place in therapy is unknown

4) Questionable primary outcome

Both studies (Thomas 2008 and Slatkin 2009) used the primary endpoint as laxation within 4 hours after first dose of methylnaltrexone. In patients who had "fewer than three laxations during the preceding week." would laxation within 12 hours be a reasonable outcome parameter? The 4 hour cutoff point is arbitrary and it seems like the focus of both trials were looking at the speed of laxation instead of whether or not patients had bowel movements. This primary outcome is problematic because it would not include bowel movements that occurred after 4 hours. However, this data might be captured in the "rescue‐free laxation within 24 hours". Data for this outcome is only reported as percentages for laxations within 24 hours instead of numerical values. The FDA analysis reported details for number of laxations within 24 hours of the first dose but not for subsequent doses) (6)
It is important to note that there were no statistically significant differences between methylnaltrexone and placebo in the use of rescue therapies, enemas or disimpaction despite the statistical significance (for laxation within 4 hours) of methylnaltrexone. The incidence of weekly bowel movements was also similar in the methylnaltrexone and placebo group during the second week of Thomas et al's study. A better way of looking at this would be to count all bowel movements then break it down by time and then compared whether it is rescue free laxation or not.
Based on the pharmacokinetic parameter differences it is almost certain that methylnaltrexone would be superior to other laxatives within the 4 hour window. However, the clinical relevance question mentioned above still remains therefore we feel better outcome may have been to assess what is normal bowel frequency in these patients and see how many of them returned to normal bowel frequency.
Camilleri et al conducted a phase 3, placebo‐controlled trial that looked at the efficacy, safety, and effect on quality of life of prucalopride in patients with severe chronic constipation. In this study, their primary efficacy end points were proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Future studies can consider adopting these primary endpoints instead of laxation within 4 hours (7)

Implication – Clinical relevancy of primary outcome is questionable.

5) Missing data and questionable data collection

It appears data for 6 people are missing from Figure 2 Panel B compared to the number of patients randomized in the study by Thomas 2008. In figure 1, 104 patients (52 in methylnaltrexone group and 54 in placebo group) completed the study; however, only 98 patients (47 in methylnaltrexone group and 51 in placebo group) can be accounted for in Figure 2 Panel B's Day 13 results. We are not sure what happened to these 6 patients.

Also from Figure 2 Panel B, the numbers of patients responding on days between doses are missing. The data for patients who had bowel movement between doses, is not shown.

Implication – Difficult to assess methylnaltrexone true effect without knowledge of the missing data and data collection process.

6) Interpretation of drugs beneficial effect problematic

Both studies (Thomas 2008 and Slatkin 2009) allowed patients to continue their baseline laxative regimen throughout the study and take rescue laxatives as needed, though not within 4 hours before or after receiving a dose of the study drug. Here is a scenario ‐ If a patient was given senna 5 hours prior to the study drug and patient had a bowel movement 1 hour after methylnaltrexone, it would be difficult to assess whether it is due to senna or methylnaltrexone. More importantly, both studies did not report the number of patients who received rescue laxatives.

Implication – Difficult to assess whether patients who had bowel movements were due to methylnaltrexone or baseline laxative regimen.

7) Impact on quality of life – not assessed

Quality of life was not assessed in either study – This is especially important given the patient population that would be on methylnaltrexone. It would be interesting to see whether methylnaltrexone has an impact on patients' quality of life. Another way of looking is that methylnaltrexone rapidly induced laxation compared to other laxatives but does this speed translate to an improved quality of life.

Implication – Quality of life data is unknown.

8) Inclusion criteria – clinical practice implication

Study population included many patients who did not report severe constipation at baseline and whose background regimens were not optimized. About one‐third of patients in the trials were receiving only one class of laxative at baseline. In addition, the median number of laxative drugs classes used was only 2.

Implication – Methylnaltrexone place in therapy is unknown.

9) Length of study

One study (Slatkin 2009) was a single dose trial while the other study (Thomas 2008) was only two weeks in duration. It would be interesting to see a trial with longer follow up period in order to assess long‐term effects of methylnaltrexone.

Implication – Long term efficacy and safety data are unknown.

References:

Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD003448. DOI: 10.1002/14651858.CD003448.pub3.
Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid‐induced constipation in advanced illness. New England Journal of Medicine 2008;358:2332–2343. [18509120]
Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid‐induced constipation in advanced illness patients. Journal of Supportive Oncology 2009;7:39–46.
Safety Information. (2010). Relistor (methylnaltrexone bromide) subcutaneous injections. Retrieved from http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm221639.htm.
Drug and Health Products. (2010). Health Canada Endorsed Important Safety Information on RELISTOR® (methylnaltrexone bromide). Retrieved from http://www.hc‐sc.gc.ca/dhp‐mps/alt_formats/pdf/medeff/advisories‐avis/prof/2010/relistor_hpc‐cps‐eng.pdf.
Drug Approval Package. (2008). Relistor (Methylnaltrexone Bromide) Subcutaneous Injection Medical Review. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000TOC.cfm.
Camilleri M, Kerstens R, Vandeplassche L. A Placebo‐Controlled Trial of Prucalopride for Severe Chronic Constipation. New England Journal of Medicine 2008; 358:2344–54.

Reply

1) Factors that could affect overall beneficial treatment effect due to differences at baseline between treatment groups

Implication – It is possible that these issues can affect the overall treatment effect; however, it would be difficult to assess whether it was overestimated or underestimated.

Our response: Yes it is difficult to assess the effect of these differences, but as the trial authors state these were not statistically significant. We conclude in review that further larger, independent trials are needed.

2) Questionable dosing regimen

Implication – Once effective, is there a need to continue regular dosing?

Our response: Dosing regimes in clinical studies and those used in the clinical setting may differ. We did not highlight this in the review, but we will in future updates. We state in our conclusions that the drug has not been fully evaluated on safety.

3) Questionable place of therapy

Implication – Methylnaltrexone place in therapy is unknown.

Our response: Yes none of the studies compared methylnaltrexone with an alternative pharmacological regimen. Therefore, the efficacy or safety of these compounds relative to other interventions is unknown. This we noted in the discussion section.

4) Questionable primary outcome

Implication – Clinical relevancy of primary outcome is questionable.

Our response: We agree that the long‐term effect of methylnaltrexone has not been established and this is one of our review recommendations.

There is no gold standard in assessing the effects of laxatives. It is acknowledged that other authors use alternative endpoints.

5) Missing data and questionable data collection

Implication – Difficult to assess methylnaltrexone true effect without knowledge of the missing data and data collection process.

Our response: Yes the trialist do not provide information on why there is missing data on 6 patients at day 13. However, we did not use this data in our meta‐analysis.

6) Interpretation of drugs beneficial effect problematic

Implication – Difficult to assess whether patients who had bowel movements were due to methylnaltrexone or baseline laxative regimen.

Our response: We agree that it is difficult to assess whether patients had bowel movements due to methylnaltrexone or baseline laxative regimen. However methylnaltrexone is used as an adjuvant when response to laxatives has been insufficient. It is not used as an alternative to regular laxatives.

We call for further trials, and we highlight through the review use of rescue laxatives in trial participants. We note that neither study reports the number of patients who received rescue laxatives.

7) Impact on quality of life – not assessed

Implication – Quality of life data is unknown.

Our response: We agree it is unknown the impact on quality of life. We did not highlight this in our review, but if further trials do not evaluate quality of life we will discuss this in future updates of this review.

8) Inclusion criteria – clinical practice implication

Implication – Methylnaltrexone place in therapy is unknown.

Our response: The review evaluated whether trials demonstrated an effect of methylnaltrexone as an adjunctive laxative in patients with opioid induced constipation. We think that the trials demonstrate an effect.

Each medical unit has it's own individual preferences on optimal laxative prescribing. As a consequence the choice of drug and dosing schedule is dependant on individual preferences. Further research needs to be done to explore the drugs place in therapy.

9) Length of study

Implication – Long term efficacy and safety data are unknown.

Our response: Yes we call for this too.

Contributors

Adrian Tookman, Bridget Candy (authors), Kate Seers (Feedback Editor), Aaron Tejani and Damen Man (Feedback comments).

What's new

Date	Event	Description
14 December 2017	New citation required and conclusions have changed	Four new studies identified, bringing the total included to eight. In total, 1022 male and female adults with cancer irrespective of stage or at a palliative care stage of any disease were randomised across the studies. A GRADE assessment was added. There are new conclusions on naldemedine. The conclusions on methylnaltrexone and naloxone have not changed.
13 November 2017	New search has been performed	This review has been updated to include results of a new search on 29 August 2017

Open in a new tab

History

Protocol first published: Issue 1, 2007  Review first published: Issue 2, 2008

Date	Event	Description
11 May 2011	New citation required and conclusions have changed	The inclusion criteria have changed. We now include patient populations of cancer and palliative care, and assess the intervention mu‐opioid antagonists for opioid‐induced bowel dysfunction. The methods have changed to reflect current Cochrane guidelines and changes to the inclusion criteria. There are new conclusions on the mu‐opioid antagonist naldemedine. Conclusions on other mu‐opioid antagonists have not changed. A Summary of Findings Table has been added.
24 September 2010	Amended	Contact details updated.
30 October 2008	Amended	Further RM5 changes
11 April 2008	Amended	Converted to new review format.
8 February 2008	New citation required and conclusions have changed	Substantive amendment

Open in a new tab

Acknowledgements

In this update we thank Anna Erskine, Kerry Harding, Phil Wiffen, Chris Eccleston, and Jo Abbott from the Cochrane Pain, Palliative and Supportive Care Review Group for their support. We would also like to thank James Cotteril, Andrew Moore, Erica Ramstad, Sheena Derry, Jeppe Schroll, and Gavin Wong for advice given in accessing unpublished trial data. We also acknowledge the two pharmaceutical companies, Mundipharma GmbH and Shionogi Limited, that responded to our letter enquiring on the availability of any unpublished data. We thank representatives from Shionogi for providing us with conference abstract data previously not identified. We also acknowledge the authors of the original Cochrane Reviews who were not part of this update review; D Boyce, DB Carr, R Drake, M Goodman, ED McNicol, R Schumann, and A Tookman. Marie Curie Care supported the review authors B Candy, V Vickerstaff, and P Stone through a department programme grant.

Cochrane Review Group funding acknowledgement: this project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service, or the Department of Health.

Appendices

Appendix 1. Search strategies for searches ran 2017

157 ‐Mu‐opioid antagonists for opioid‐induced bowel dysfunction August 2017

Open in a new tab

Database searched	Date of last search	April 2016	August 2017	Total
CENTRAL (the Cochrane Library) Issue 7 of 12, 2017	30 August 2017	67	17	84
MEDLINE and MEDLINE in Process (Ovid) 2007 to 28 August 2017	29 August 2017	171	36	207
EMBASE (Ovid) 2007 to 2017 week 35	29 August 2017	264	36	300
CINAHL (EBSCO) 1982 to August 2017	29 August 2017	37	0	37
Web of Science ISI (SCI‐EXPANDED & CPCI‐S) 1945 to 28 August 2017	29 August 2017	251	32	283
Total		790	121	911
After deduplication		557	76	633

Open in a new tab

CENTRAL

#1 MESH DESCRIPTOR Constipation 920

#2 (constipat* or laxation or (bowel near2 dysfunction*)):TI,AB,KY 5843

#3 MESH DESCRIPTOR Ileus EXPLODE ALL TREES 143

#4 MESH DESCRIPTOR Gastrointestinal Motility EXPLODE ALL TREES 2592

#5 MESH DESCRIPTOR Gastrointestinal Tract EXPLODE ALL TREES 9982

#6 #1 OR #2 OR #3 OR #4 OR #5 16865

#7 MESH DESCRIPTOR Narcotic Antagonists EXPLODE ALL TREES 2776

#8 ((Naltrexone or Naloxone or Methylnaltrexone or nalmefene or Alvimopan or ADL 8‐2698 or LY246736)) or ((mu‐opioid near2 (receptor* or antagonist*)) or (pentazocine or nalbuphine or buprenorphine or dezocine or butorphanol or loperamide or PAMORA or movantik or naloxegol)):TI,AB,KY 5872

#9 MESH DESCRIPTOR Receptors, Opioid EXPLODE ALL TREES 348

#10 ((neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*)):TI,AB,KY 94907

#11 MESH DESCRIPTOR neoplasms EXPLODE ALL TREES 45998

#12 ((palliat* or terminal* or endstage or hospice* or (end near3 life) or (care near3 dying) or ((advanced or late or last or end or final) near3 (stage* or phase*)))):TI,AB,KY 15402

#13 MESH DESCRIPTOR Palliative Care 1214

#14 MESH DESCRIPTOR Terminal Care EXPLODE ALL TREES 314

#15 #12 OR #13 OR #14 15418

#16 #10 OR #11 99655

#17 #7 OR #8 OR #9 6102

#18 #15 OR #16 110040

#19 #6 AND #17 AND #18 95

#20 2007 TO 2016:YR 360460

#21 #19 AND #20 67

MEDLINE

1 Constipation/ (11563)

2 (constipat* or laxation or (bowel adj2 dysfunction*)).tw. (16978)

3 exp Ileus/ (4645)

4 exp Gastrointestinal Motility/ (34225)

5 exp Gastrointestinal Tract/ (578429)

6 1 or 2 or 3 or 4 or 5 (610305)

7 exp Narcotic Antagonists/ (34192)

8 (Naltrexone or Naloxone or Methylnaltrexone or nalmefene or Alvimopan or ADL 8‐2698 or LY246736 or MNTX or oxycodone or targinact).mp. (32527)

9 ((mu‐opioid adj2 (receptor* or antagonist*)) or (pentazocine or nalbuphine or buprenorphine or dezocine or butorphanol or loperamide or PAMORA or movantik or naloxegol )).mp. (16793)

10 exp Receptors, Opioid/ (23399)

11 or/7‐10 (58741)

12 (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*).tw. (2224162)

13 exp Neoplasms/ (2813163)

14 12 or 13 (3230772)

15 (palliat* or terminal* or endstage or hospice* or (end adj3 life) or (care adj3 dying) or ((advanced or late or last or end or final) adj3 (stage* or phase*))).tw. (571727)

16 Palliative Care/ (44067)

17 exp Terminal Care/ (43534)

18 15 or 16 or 17 (610189)

19 14 or 18 (3708789)

20 6 and 11 and 19 (435)

21 randomized controlled trial.pt. (411978)

22 controlled clinical trial.pt. (90457)

23 randomized.ab. (308871)

24 placebo.ab. (157136)

25 drug therapy.fs. (1841827)

26 randomly.ab. (218163)

27 trial.ab. (319135)

28 groups.ab. (1379535)

29 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 (3495620)

30 exp animals/ not humans.sh. (4221321)

31 29 not 30 (2977237)

32 20 and 31 (239)

33 (2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016*).ed. (7189774)

34 32 and 33 (171)

Embase

1 Constipation/ (66990)

2 (constipat* or laxation or (bowel adj2 dysfunction*)).tw. (31395)

3 exp Ileus/ (10689)

4 exp Gastrointestinal Motility/ (29756)

5 exp Gastrointestinal Tract/ (36303)

6 1 or 2 or 3 or 4 or 5 (144623)

7 exp Narcotic Antagonist/ (56632)

8 (Naltrexone or Naloxone or Methylnaltrexone or nalmefene or Alvimopan or ADL 8‐2698 or LY246736 or MNTX or oxycodone or targinact).mp. (64688)

9 ((mu‐opioid adj2 (receptor* or antagonist*)) or (pentazocine or nalbuphine or buprenorphine or dezocine or butorphanol or loperamide or PAMORA or movantik or naloxegol)).mp. (40254)

10 exp Opiate receptor/ (33249)

11 or/7‐10 (111413)

12 exp neoplasm/ (3639889)

13 (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*).tw. (3148234)

14 12 or 13 (4328511)

15 (palliat* or terminal* or endstage or hospice* or (end adj3 life) or (care adj3 dying) or ((advanced or late or last or end or final) adj3 (stage* or phase*))).tw. (734729)

16 exp palliative therapy/ (77974)

17 terminal care/ or hospice care/ (33098)

18 15 or 16 or 17 (770267)

19 14 or 18 (4905872)

20 6 and 11 and 19 (1858)

21 random$.tw. (1070907)

22 factorial$.tw. (27377)

23 crossover$.tw. (56887)

24 cross over$.tw. (25402)

25 cross‐over$.tw. (25402)

26 placebo$.tw. (235531)

27 (doubl$ adj blind$).tw. (166956)

28 (singl$ adj blind$).tw. (17421)

29 assign$.tw. (283715)

30 allocat$.tw. (102682)

31 volunteer$.tw. (205346)

32 Crossover Procedure/ (46656)

33 double‐blind procedure.tw. (234)

34 Randomized Controlled Trial/ (400175)

35 Single Blind Procedure/ (21855)

36 or/21‐35 (1679747)

37 (animal/ or nonhuman/) not human/ (5008260)

38 36 not 37 (1491043)

39 20 and 38 (352)

40 (2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016*).dd. (13117895)

41 39 and 40 (264)

CINAHL

S29 S28 AND S20

S28 S23 or S27

S27 S24 OR S25 OR S26

S26 (MH "Terminal Care+")

S25 (MH "Palliative Care")

S24 (palliat* or terminal* or endstage or hospice* or (end N3 life) or (care N3 dying) or ((advanced or late or last or end or final) N3 (stage* or phase*)))

S23 S21 or S22

S22 (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*)

S21 (MH "Neoplasms+")

S20 S19 and S10

S19 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18

S18 (allocat* random*)

S17 (MH "Quantitative Studies")

S16 (MH "Placebos")

S15 placebo*

S14 (random* allocat*)

S13 (MH "Random Assignment")

S12 (Randomi?ed control* trial*)

S11 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or (singl* mask* )

S10 S5 AND S19

S9 S6 or S7 or S8

S8 ((mu‐opioid N2 (receptor* or antagonist*))or (pentazocine or nalbuphine or buprenorphine or dezocine or butorphanol or loperamide or PAMORA or movantik or naloxegol )

S7 (Naltrexone or Naloxone or Methylnaltrexone or nalmefene or Alvimopan or ADL 8‐2698 or LY246736 or MNTX or oxycodone or targinact)

S6 (MH "Narcotic Antagonists+")

S5 S1 OR S2 OR S3 OR S4

S4 (MH "Gastrointestinal Motility+")

S3 (MH "Intestinal Obstruction+")

S2 (constipat* or laxation or (bowel N2 dysfunction*))

S1 (MH "Constipation")

Web of Science

#19 #15 and #18

#18 #17 or #16

#17 ((palliat* or terminal* or endstage or hospice* or (end near/3 life) or (care near/3 dying) or ((advanced or late or last or end or final) near/3 (stage* or phase*))))

#16 ((neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*))

#15 #14 AND #9

#14 #13 OR #12 OR #11 OR #10

#13 TS=trial* OR TI=trial*

#12 TI=clin* OR TS=clin*

#11 TI=randomi* OR TS=randomi*

#10 TS=Randomized clinical trial* OR TI=Randomized clinical trial*

#9 #8 AND #5

#8 #7 OR #6

#7 TOPIC: (((mu‐opioid near/2 (receptor* or antagonist*)) or ((pentazocine or nalbuphine or

buprenorphine or dezocine or butorphanol or loperamide or PAMORA or movantik or naloxegol))

#6 TOPIC: ((Naltrexone or Naloxone or Methylnaltrexone or nalmefene or Alvimopan or ADL 8‐2698 or LY246736 or MNTX or oxycodone or targinact))

#5 #4 OR #3 OR #2 OR #1

#4 TOPIC: ("Gastrointestinal Tract")

#3 TOPIC: ("Gastrointestinal Motility")

# 2 TOPIC: (Ileus)

# 1 TOPIC: ((constipat* or laxation or (bowel near/2 dysfunction*)))

Appendix 2. Letter to pharmaceutical companies

Example, as was sent to AstraZeneca, of letter sent to pharmaceutical companies

Research and Communications

Manager (or equivalent)

AstraZeneca (Global HQ)

Floors 7‐9,

2 Kingdom Street,

Paddington Central,

London, W2 6BD, UK

Email: b.candy@ucl.ac.uk

Phone: +44 020767997

March 31st 2016

Dear Sir or Madam

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in cancer and palliative care patients ‐ a Cochrane systematic review

We address you in order to request your assistance. We are conducting a systematic review on the effect of mu‐opioid antagonists for opioid‐induced bowel dysfunction in cancer and palliative care patients. We are working with the Cochrane Pain, Palliative and Supportive Care Review Group (www.papas.cochrane.org).

Our systematic review intends to include all relevant literature empirically describing both the positive and possibly negative effects of mu‐opioid antagonists. We believe that conducting this review is in the common interest of patients, doctors and pharmaceutical manufacturers. Furthermore, it is an important ethical issue. The results from this review will, in the future, guide authorities, clinicians and researchers when it comes to considering the use of a mu‐opioid antagonist in the treatment of opioid‐induced bowel dysfunction for cancer and palliative care patients.

Our Cochrane review will be comprehensive. The currently included studies come from our search for literature through international scientific databases. However, the published literature only provides us with limited and possibly selective knowledge, since it is unlikely that all studies and data are available through these databases. By contacting authors of significant publications, experts in the field and pharmaceutical companies, we hope to be informed of additional studies, published as well as unpublished. This approach has been used in other Cochrane systematic reviews investigating medical preparations for common illnesses such as Attention Deficit Hyperactivity Disorder (http://www.bmj.com/content/351/bmj.h5203).

We hope you will assist us with providing studies and data that are relevant for our review. We are aware from searches of electronic citation databases including PubMed and clinicaltrials.gov of one trial for which AstraZeneca are the responsible party/study sponsors (NCT01384292). As previously noted, we are interested in data regarding both positive and negative effects of mu‐opioid antagonists for opioid‐induced bowel dysfunction in cancer and palliative care patients, from randomised clinical trials, regardless of the year the data were recorded or published.

We will state which companies we have been in contact with, and acknowledge those who have assisted us with provision of data. We would be happy to meet a representative from your company if you would like to speak in person. If you have any questions, please contact us.

Enclosed below in this letter is a list of the currently included studies in our review.

We look forward to your response.

Yours faithfully

Bridget Candy  PhD, Senior Research Fellow  University College London,

6th Floor, Maple House,

149 Tottenham Court Road,

London W1T 7NF, UK

Phone: +44 02076799713  E‐mail: b.candy@ucl.ac.uk

  Louise Jones

Senior Clinical Lecturer

University College London,

6th Floor, Maple House,

149 Tottenham Court Road,

London W1T 7NF, UK

Patrick Stone

Professor of Palliative and End of Life Care,

Marie Curie Palliative Care Research Department

University College London,

6th Floor, Maple House,

149 Tottenham Court Road,

London W1T 7NF, UK

Phil Larkin  Professor of Clinical Nursing

School of Nursing, Midwifery and Health Systems,

University College Dublin, Belfield, Dublin 4, Republic of Ireland

Vicky Vickerstaff

Statistician

University College London,

6th Floor, Maple House,

149 Tottenham Court Road,

London W1T 7NF, UK

(copy sent via info@astrazeneca.com)

List of the currently included studies in our review

Ahmedzai SH, Nauck F, Bar‐Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double‐blind, active‐ controlled, double‐dummy, parallel‐group study to determine the safety and efficacy of oxycodone/naloxone prolonged‐release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine 2012; 26: 50‐60.

Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed‐Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid‐Induced Constipation: Results of a Randomized, Placebo‐Controlled Study and Open‐Label Extension. Journal of Palliative Medicine 2015;18:593‐600.

Chamberlain BH, Cross K, Winston JL , Thomas J, Wang W, Su C, Israel RJ. Methylnaltrexone Treatment of Opioid‐Induced Constipation in Patients with Advanced Illness. Journal of Pain and Symptom Management 2009;38: 683‐90.

Portenoy RK, Thomas J, Moehl Boatwright ML, Galasso FL, Stambler N, Von Gunten CF, et al. Subcutaneous methylnaltrexone for the treatment of opioid‐induced constipation in patients with advanced illness: a double‐ blind, randomised, parallel group, dose‐ranging study. Journal of Pain and Symptom Management 2008;35: 458‐68.

Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid‐induced constipation in advanced illness patients. Journal of Supportive Oncology 2009;7: 39‐46.

Sykes NP. An investigation of the ability of oral naloxone to correct opioid‐related constipation in patients with advanced cancer. Palliative Medicine 1996;10:135‐44.

Thomas J, Karver S, Cooney GA, et al. A randomized, placebo‐controlled trial of subcutaneous methylnaltrexone for the treatment of opioid‐ induced constipation in patients with advanced illness. New England Journal of Medicine 2008;358: 2332‐4.

Data and analyses

Comparison 1. Methylnatrexone versus placebo: rescue‐free laxation:

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Within 24 hours of dose	2	287	Risk Ratio (M‐H, Fixed, 95% CI)	2.77 [1.91, 4.04]
2 Within 4 hours after 4 of the 7 doses	2	305	Risk Ratio (M‐H, Fixed, 95% CI)	9.98 [4.96, 20.09]
3 Within 4 hours of first dose	3	517	Risk Ratio (M‐H, Fixed, 95% CI)	3.87 [2.83, 5.28]
4 Within 4 hours after 1 or 2 doses of the first 4 doses	2	363	Risk Ratio (M‐H, Fixed, 95% CI)	6.89 [4.46, 10.66]
5 Improvement in constipation distress at day 1	2	287	Risk Ratio (M‐H, Fixed, 95% CI)	1.87 [1.34, 2.59]
6 Participant global impression of improvement in bowel status at 1 week	2	287	Risk Ratio (M‐H, Fixed, 95% CI)	2.32 [1.64, 3.27]
7 Clinician global impression of improvement in bowel status at 1 week	2	287	Risk Ratio (M‐H, Fixed, 95% CI)	2.37 [1.66, 3.38]

Open in a new tab

1.4. Analysis.

Open in a new tab

Comparison 1 Methylnatrexone versus placebo: rescue‐free laxation:, Outcome 4 Within 4 hours after 1 or 2 doses of the first 4 doses.

Comparison 2. Methylnaltrexone versus placebo: serious adverse event.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Serious adverse event	2	364	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.38, 0.93]

Open in a new tab

Comparison 3. Methylnaltrexone versus placebo: adverse event.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Adverse events	3	518	Risk Ratio (M‐H, Random, 95% CI)	1.17 [0.94, 1.45]
2 Dropouts due to adverse event	2	363	Risk Ratio (M‐H, Fixed, 95% CI)	1.22 [0.54, 2.76]

Open in a new tab

Comparison 4. Oxycodone/naloxone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Adverse events	2	234	Risk Ratio (M‐H, Fixed, 95% CI)	1.08 [0.94, 1.24]

Open in a new tab

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Ahmedzai 2012.

Methods	Randomised, parallel, controlled, multi‐centre trial. International with sites in Australia, Czech Republic, France, Germany, Hungary, Israel, the Netherlands, Poland, and the UK
Participants	Aim: to investigate whether OXN PR can improve constipation and maintain analgesia compared with OXY PR tablets, in people with cancer. Inclusion criteria: people with chronic moderate/severe cancer pain and requiring 24‐h opioid therapy Exclusion criteria: clinically unstable disease or significant cardiovascular, renal, hepatic, or psychiatric disease; clinically significant gastrointestinal disease or significant structural abnormalities of the gastrointestinal tract; cyclic chemotherapy within 2 weeks before screening visit or planned during the core trial (shown in the past to influence bowel function); radiotherapy that would influence bowel function or pain during the double‐blind phase Participants: in the intervention arm; mean age 61 years and 48/92 men. In comparison arm; mean age 64 years and 46 men and 46 women. The most common primary cancer sites were breast (19%), lung (13%), and prostate (10%). 26% had bone metastases. At the start of the trial, 183/184 (99.5%) participants had constipation‐induced or worsened by their opioid medication. A similar number were also taking laxatives. All were outpatients.
Interventions	Intervention: OXN PR up to 120 mg/day, n = 92 Comparison: OXY PR up to 120 mg/day, n = 92 Duration: 4 weeks
Outcomes	Primary outcomes: symptoms of constipation as measured by Bowel Function Index, efficacy for management of chronic cancer pain as measured by the Brief Pain Inventory‐Short Form Secondary outcomes: use of rescue medication, quality of life, and safety Outcomes measured: at 4 weeks
Notes	Funding: Mundipharma GmbH Trial registration: NCT00513656/OXN2001
*Risk of bias*
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were assigned to treatments (1:1 allocation ratio) using a pseudo‐random number generator in a computer program."
Allocation concealment (selection bias)	Low risk	Quote: "randomisation schedule prepared by the Clinical Supplies Department of the Sponsor or an associated company."
Blinding (performance bias and detection bias)   All outcomes	Unclear risk	Stated double‐blind, no further details provided
Incomplete outcome data (attrition bias)   All outcomes	Low risk	133/184 completed the trial. Less than a third in each group dropped out. Similar proportion dropped out in each group
Selective reporting (reporting bias)	Unclear risk	No details provided
Sample size	Unclear risk	50‐199 participants per treatment arm

Open in a new tab

Bull 2015.

Methods	Randomised, controlled, parallel, multi‐centred trial in the USA
Participants	Aim: to determine the efficacy and safety of fixed‐dose subcutaneous methylnaltrexone in people with advanced illness and opioid‐induced constipation in a variety of healthcare situations (inpatient, outpatient, home, hospice, and long‐term care facilities). Inclusion criteria: participants aged > 18 years with advanced illness and a life expectancy of ≥ 1 month and opioid‐induced constipation (< 3 BM in the last week and no BM in 24 h or 48 h) and who were receiving stable doses of laxatives and opioids Exclusion criteria: people with a disease process suggestive of gastrointestinal obstruction or clinically significant active diverticular disease, fecal impaction, peritonitis, bowel surgery 10 days before dosing, or fecal ostomy, or with a bodyweight < 38 kg Participants: 118 men and 112 women. Mean age in intervention arm 65.3 years (SD 12.9) and in placebo arm 65.7 years (SD 13.0). 216/230 of white race. Primary diagnosis cancer in 66% of participants (152/230). The majority (58/78) of the other participants had pulmonary, cardiovascular, or neurological disease
Interventions	Intervention: subcutaneous methylnaltrexone 8 mg (bodyweight of 38 kg to < 62 kg) or 12 mg (bodyweight > 62 kg), n = 116 Comparison: placebo, n = 114 Duration: both were administered every other day over 2 weeks
Outcomes	Primary outcome: percentage of participants with RFBM within 4 h after at the most 2 of the doses in the first week of treatment Secondary outcomes: % with the first RFBM within 4 h after the first dose, number of BMs within 24 h after dosing per week Outcomes measured: over 2 weeks
Notes	Funding: technical editorial and medical writing assistance from Salix Pharmaceuticals Limited Trial registration: NCT00672477
*Risk of bias*
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly assigned." No other details
Allocation concealment (selection bias)	Unclear risk	Quote: "randomly assigned." No other details
Blinding (performance bias and detection bias)   All outcomes	Unclear risk	Stated double blind, no further details provided
Incomplete outcome data (attrition bias)   All outcomes	Low risk	27/116 in the intervention group and 20/114 in placebo were lost to follow‐up. Reason for loss were similar in both trial arms.
Selective reporting (reporting bias)	Unclear risk	No details
Sample size	Unclear risk	50‐199 participants per treatment arm

Open in a new tab

Dupoiron 2017.

Methods	Randomised, controlled, parallel trial unclear what country participants were from
Participants	Aim: to evaluate the tolerability and efficacy of OXN PR doses up to oxycodone/naloxone 160 mg/80 mg compared with OXY PR formulation. Inclusion criteria: adults with cancer and non‐cancer pain requiring opioids on a stable dose of OXY PR for ≥ 4 consecutive days prior to randomisation and have a pain score of ≤ 4 with ≤ 2 doses of OXY PR analgesic rescue medication per day for either the last 3 consecutive days or 4 of the last 7 days. Constipation caused or aggravated by opioids was confirmed by the participant and the investigator and evidenced by a medical need of regular laxatives to have ≥ 3 bowel evacuations per week or by having < 3 bowel evacuations when not taking a laxative Exclusion criteria: included hypersensitivity to oxycodone, naloxone; active alcohol or drug abuse or history of opioid abuse (or both); unreported illicit drug use (including cannabis); any condition in which opioids were contraindicated or if they had diarrhoea Participants: 100 men and 143 women randomised, of which a subsample, 46, were people with cancer pain. Mean age in whole sample 57.9 years (SD 11.03) in OXN PR arm and 57.5 years (SD 12.33) in OXY PR arm. Subsample demographics on people with cancer not provided
Interventions	Intervention: starting dose during the double‐blind phase dependent on the effective, stable analgesic dose established in the run‐in period, titration up to maximum daily dose of OXN PR 160 mg/80 mg was permitted after 1 week Comparison: OXY PR equivalent dosage to participants in the intervention arm Duration: up to 5 weeks
Outcomes	Primary outcomes: change in mean bowel function scores, pain scores Secondary outcomes: analgesic and laxative rescue medication, complete SBMs, and quality of life (EuroQol EQ‐5D‐3L) Outcomes measured: 1, 2, 4, and 5 weeks
Notes	Funding: Mundipharma GmbH Trial registration: NCT01438567 Study comprised of 3 phases: prerandomisation phase consisting of a screening period and a run‐in period, a double‐blind phase, and an extension phase. In the run‐in phase, OXY PR was titrated to analgesic effect to determine the starting dose to be used after randomisation.
*Risk of bias*
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly assigned." No other details
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias)   All outcomes	Unclear risk	Double‐blind, participant blinded, no other details on who else was blinded
Incomplete outcome data (attrition bias)   All outcomes	Unclear risk	16/120 men and 18/123 women in whole sample dropped out per arm. Number who dropped in the subset of 46 people with cancer not reported
Selective reporting (reporting bias)	Low risk	Bias was unlikely as the trial listed in clinical trial registry reported same primary and secondary outcomes that were presented in the paper
Sample size	High risk	< 50 participants per treatment arm in subsample of people with cancer

Open in a new tab

Katakami 2017.

Methods	Randomised, controlled, parallel, multi‐centred trial in Korea and Japan
Participants	Aim: to evaluate the dose, efficacy, and safety of naldemedine for the treatment of opioid‐induced constipation in people with cancer in Japan and Korea. Inclusion criteria: adults aged ≥ 18 years with cancer pain, stable regimen of opioid for > 2 weeks, complicated with opioid‐induced constipation despite regular laxative use Exclusion criteria: constipation potentially attributable to causes other than opioid analgesics Participants: 134 men and 93 women entered trial. Mean age by trial arm: naldemedine 0.1 mg daily: 65.8 years (SD 11.5), naldemedine 0.2 mg daily: 63.4 years (SD 10.4), naldemedine 0.4 mg daily: 64.2 years (SD 10.7); placebo: 64.2 (SD 9.6). Most participants had lung cancer, other cancers included breast and colorectal. All as graded by the ECOG Performance Status were ambulatory. Care setting not stated
Interventions	Intervention 1: naldemedine 0.1 mg daily, n = 56 Intervention 2: naldemedine 0.2 mg daily, n = 58 Intervention 3: naldemedine 0.4 mg daily, n = 56 Comparison: placebo, n = 57 Duration: all administered daily for 2 weeks
Outcomes	Primary outcome: change from baseline in the frequency of SBM per week Secondary outcomes: SBM responder rate, change from baseline in frequency of complete SBM, change from baseline in frequency of SBM without straining, adverse events, and opiate withdrawal Outcomes measured: over 2 weeks
Notes	Funding: Shionogi and Co Ltd Trial registration: JapicCTI‐111510
*Risk of bias*
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Achieved "using the dynamic allocation procedure of the registration center, where the maximum intergroup difference in the participant number at each study site did not exceed two."
Allocation concealment (selection bias)	Unclear risk	Probably occurred as allocation provided remotely but not stated specifically
Blinding (performance bias and detection bias)   All outcomes	Low risk	All study team members and participants were blinded to treatment.
Incomplete outcome data (attrition bias)   All outcomes	Low risk	2 participants, 1/57 in placebo group and 1/56 in naldemedine 0.1 mg were lost to follow‐up.
Selective reporting (reporting bias)	Unclear risk	No details
Sample size	Unclear risk	50‐199 participants per treatment arm

Open in a new tab

Portenoy 2008.

Methods	Randomised, controlled, multi‐centre, parallel‐group trial in the USA
Participants	Aim: to assess the efficacy and safety of subcutaneous methylnaltrexone in a population of people with advanced illness and opioid‐induced constipation, and to clarify whether there was a dose‐response relationship for the purpose of dose selection in further clinical evaluations. Inclusion criteria: advanced disease (defined as terminal or end‐stage, such as advanced metastatic cancer and AIDS but with a life expectancy of ≥ 4 weeks and stable vital signs) for which they were receiving palliative care and were receiving any opioid drug on a daily basis at a dose that had been stable for ≥ 2 weeks and were expected to remain stable for an additional ≥ 4 weeks, and despite no or conventional laxative therapy they had no BMs for 2 days and reported ongoing constipation, defined as > 2 days with no BM and a score of ≥ 3 on a 5‐point scale assessing constipation‐related distress Exclusion criteria: fever or otherwise unstable vital signs; liver function test 3 times the upper limit of normal, serum creatinine level 2 times the upper limit, or a platelet count < 50,000/mm³; new regimen or dose change of concurrent gastrointestinal motility‐altering medications during 3 weeks prior to trial enrolment; history of gastrointestinal obstruction or other condition that could compromise drug action; diagnosis of active peritoneal cancer; history of peritoneal catheter placement for chemotherapy or dialysis; known hypersensitivity to methylnaltrexone, naltrexone, or naloxone; or if any investigational drug or experimental product had been administered within the previous 30 days Participants: 15 men and 18 women. Mean age 61 years (SD 19.0) (range 20‐87 years). 79% were white people. Primary diagnoses at baseline were 28/33 cancer, 3 sickle cell disease, and 2 AIDS. 88% of participants were receiving a laxative at baseline. The mean opioid (morphine equivalent) dose at baseline was 289.9 mg/day (SD 308.0), median 180 mg/day, range 9‐1207 mg/day. Mean number of BMs per week was 1.9. Care setting not stated
Interventions	Intervention 1: subcutaneous methylnaltrexone 1 mg, n = 10 Intervention 2: subcutaneous methylnaltrexone 5 mg, n = 7 Intervention 3: subcutaneous methylnaltrexone 12.5 mg, n = 10 The initial dose range of 1 mg, 5 mg, or 12.5 mg was extended by adding a 20 mg group (n = 6) during the trial while still maintaining the double‐blind. Duration: 3 doses over 1 week
Outcomes	Primary outcomes: laxative response (BM) within 4 h of the initial dose. Secondary outcomes: laxation within 4 h of subsequent doses, during the 24‐h period after each dose, time to laxation, use of rescue laxatives, subjective outcomes of constipation‐associated symptoms, pain intensity, symptoms potentially due to opioid withdrawal or adverse events, and participant satisfaction Outcomes measured: up to 24 h per dose, and 30 days after last dose
Notes	Funding: Progenics Pharmaceuticals Trial registration: none provided
*Risk of bias*
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "After providing consent, patients were initially randomised in a ratio of 1:1:1 to receive 1 mg, 5 mg, or 12.5 mg of methylnaltrexone."
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias)   All outcomes	Unclear risk	Double‐blind, participant blinded, no other details on who was blinded
Incomplete outcome data (attrition bias)   All outcomes	Low risk	22/33 completed trial. 7 discontinued "at patient request", three from the 12.5 mg arm and one each from the 1 mg and 5 mg arm and two from 20 mg arm. One in the 20mg arm discontinued because of "intolerable" adverse event
Selective reporting (reporting bias)	Unclear risk	No details provided
Sample size	High risk	< 50 participants per treatment arm

Open in a new tab

Slatkin 2009.

Methods	Randomised, controlled, parallel‐group, multi‐centre controlled trial
Participants	Aim: to assess the safety and efficacy of a single subcutaneous injection of methylnaltrexone (0.15 mg/kg or 0.3 mg/kg) versus placebo. Inclusion criteria: aged > 18 years, advanced illness (such as incurable cancer or end‐stage AIDS and life expectancy 1‐6 months) and opioid‐induced constipation. On a stable opioid regimen for the control of pain/discomfort for ≥ 3 days before randomisation, had a stable scheduled laxative regimen for ≥ 3 days prior to treatment, no clinically significant laxation within 48 h prior to the first trial drug dose, had stable vital signs, and not pregnant and using an effective method of birth control. Baseline laxative regimens taken at time of trial entry could be continued throughout the trial. Rescue laxatives, defined as laxatives administered on an as needed basis were allowed but not within 4 h before or after administration of the double‐blind dose. Exclusion criteria: previous treatment with methylnaltrexone, naltrexone, or naloxone; recent participation in any other studies involving investigational products; any disease process suggestive of gastrointestinal obstruction; any potential non‐opioid cause of bowel dysfunction; history of current peritoneal catheter for intraperitoneal administration, chemotherapy administration, or dialysis; clinically active diverticular disease; evidence of faecal impaction; surgically acute abdomen; faecal ostomy; pregnancy; or breastfeeding Participants: 84 American men and 70 American women at 17 hospice and other palliative care settings. Mean age 65.3 years (SD 14.96). Primary diagnosis cancer (125/154), cardiovascular disease (8), HIV/AIDS (1), and other (20). Apart from 8 participants, all had some level of constipation distress. 95% were using a laxative. Oral morphine equivalents, median mg/day 186.5, range 8‐12,2560 mg/day
Interventions	Intervention 1: single subcutaneous injection methylnaltrexone 0.15 mg/kg, n = 47 Intervention 2: single subcutaneous injection methylnaltrexone 0.3 mg/kg, n = 55 Comparison: placebo, n = 52 Duration: 1‐week double‐blind phase, followed by 28‐day open phase
Outcomes	Primary outcome: proportion of participants with rescue‐free laxation (a significant BM) within 4 h after administration of the double‐blind dose. Participants needing rescue laxative or disimpaction within 4 h of dosing were considered non‐responders. Secondary outcomes: proportion of participants with rescue‐free laxation within 24 h postdosing; improvement in GCIC scale (defined as a rating of slightly better, somewhat better, or much better); improvement in constipation distress (defined as a change by at least 1 category toward none); improvement in stool consistency; changes in baseline pain, symptoms/signs of central opioid withdrawal, and adverse events Outcomes measured: to 6 days following first dose
Notes	Funding: Progenics Pharmaceuticals Trial registration: 301/NCT00401362
*Risk of bias*
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "...randomly assigned in blocks of three to the three treatment groups in a 1:1:1 ratio. Computer‐generated randomisation scheme performed by a statistician external to the sponsor."
Allocation concealment (selection bias)	Low risk	Quote: "computer‐generated randomisation scheme performed by a statistician external to the sponsor."
Blinding (performance bias and detection bias)   All outcomes	Low risk	Quote: "...syringe contents were blinded to patients and staff administering injections." "each syringe had identical volume."
Incomplete outcome data (attrition bias)   All outcomes	Low risk	152/154 completed trial (1 died and 1 was non‐compliant both in trial arm of higher dose of methylnaltrexone) Analysis on an intention‐to‐treat basis
Selective reporting (reporting bias)	Unclear risk	No details
Sample size	High risk	< 50 participants in 1 of the 2 treatment arms Although this risk was not relevant to some of our analysis. This is when we combined the trials 2 treatment groups in our exploration of the impact of mu‐opioid antagonists in comparison with placebo.

Open in a new tab

Sykes 1996.

Methods	Randomised, controlled, single‐centre, cross‐over trial
Participants	Aim: to assess in a dose‐ranging trial the use of oral naloxone in opioid‐related constipation in participants with advanced cancer Inclusion criteria: participants with advanced cancer receiving either morphine or diamorphine analgesia orally. All required laxatives prior to trial and their use was continued during the trial except for lactulose Exclusion criteria: fecal stomas or history of constipation prior to using opioid analgesia Participants: 13 men and 14 women patients in a UK hospice. Mean age 64 years, median 65 years, range 44‐88 years. 9 participants had breast cancer; 5 bronchus; 3 prostate; 2 oesophagus, and 1 each of rectum, kidney, bladder, stomach, colon, fallopian tube, malignant melanoma, and fibrosarcoma); 3 participants had liver metastases, 2 had hepatomegaly; no participant had constipation prior to using opioid analgesia
Interventions	Morphine or diamorphine oral (maintenance dose) Intervention: naloxone oral every 4‐h for total daily dose of 0.5%, 1%, 2%, 5%, 10%, or 20% of total daily dose of morphine. The participants received "one level" (a lower level) of naloxone. Then after 2 participants at 0.5% to 5% had received the drug without slowing bowel transit time the dose was increased. In higher doses, the increase was following no slowing effect in 4 participants, n = 17 Comparison: placebo: chloroform water, n = 17 Duration: 2 days each treatment arm (parallel washout)
Outcomes	Outcomes: small bowel transit time by lactulose/hydrogen breath test; pain by 4‐point scale (0 = no pain, 3 = severe pain)
Notes	Funding: charities, Cancer Relief Macmillan Fund, and the Wolfson Foundation. Naloxone was donated by MacFarlan Smith (pharmaceutical company). Trial registration: none
*Risk of bias*
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Stated randomised but no further details provided
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding (performance bias and detection bias)   All outcomes	Unclear risk	Stated double blind but no further details provided
Incomplete outcome data (attrition bias)   All outcomes	Low risk	Data analysis of 12 participants were reported. Of the 5 not included, 1 declined. 4 were withdrawn, 2 because of diarrhoea (1 occurred while on placebo, 1 caused by the lactulose taken as part of the small bowel transit time test), 1 was withdrawn because of general deterioration, and 1 because of nausea which the trialists felt was not related to the intervention).
Selective reporting (reporting bias)	Unclear risk	No details. The study does not declare a primary outcome
Sample size	High risk	< 50 participants per treatment arm

Open in a new tab

Thomas 2008.

Methods	Randomised, controlled, multi‐centre, parallel trial
Participants	Aim: to assess the safety and efficacy of subcutaneous methylnaltrexone for treating opioid‐induced constipation in participants with advanced illness. Inclusion criteria: participants who had a terminal illness with a life expectancy > 1 month, were receiving stable doses of opioids for analgesia and had opioid‐induced constipation (defined as ≤ 3 laxations in the previous week or no laxation in the previous 48 h) despite having taken laxatives for ≥ 3 days. Participants could continue their baseline laxative regimen throughout the trial and take rescue laxatives as needed, though not within 4 h before or after receiving a dose of the trial drug. Exclusion criteria: participants whose constipation was not primarily caused by opioids, mechanical gastrointestinal obstruction, an indwelling peritoneal catheter, clinically active diverticular disease, fecal impaction, acute surgical abdomen, and fecal ostomy Participants: 58 men and 76 women from North America. They were from 27 nursing homes, hospice sites, or other palliative care centres in the USA and Canada (78 with cancer, 15 cardiovascular disease, 14 chronic obstructive pulmonary disease, 8 dementia, and 19 with other diseases). Median age in methylnaltrexone group 70 years (range 34‐93 years) and in the placebo group 72 years (range 39‐98 years). Opioid dose: methylnaltrexone group: mean 417 mg/day, median 150 mg/day, range 9‐4160 mg/day; placebo group: mean 339 mg/day, median 100 mg/day, range 10‐10,160 mg/day. 98% in the methylnaltrexone and 99% in placebo group were using laxatives
Interventions	Intervention: subcutaneous methylnaltrexone 0.15 mg/kg bodyweight, n = 62 Comparison: placebo, n = 71 Dose every other day Duration of treatment: 2 weeks
Outcomes	Primary outcome: RFBM within 4 h after first dose Secondary outcomes: laxation within 4 h after ≥ 2 of the first 4 doses. Consistency (from watery to hard) and difficulty of laxation. Adverse events were assessed using the National Cancer Institute's Common Toxicity Criteria (rated on a scale from 'none' to 'very much'). Participants were also assessed on the Modified Himmelsbach Opiate Withdrawal Scale (on 7 symptoms including yawning, lacrimation, rhinorrhoea, perspiration, tremor, piloerection, and restlessness) Outcomes measured: over 2 weeks
Notes	Funding: Progenics Pharmaceuticals. Trial 302
*Risk of bias*
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation schedule, blocked according to trial centre
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias)   All outcomes	Low risk	Quote: "The study drugs (40 mg of methylnaltrexone per millilitre or placebo) were provided in identically appearing vials." "Syringe contents were blinded to patients and staff administering injections."
Incomplete outcome data (attrition bias)   All outcomes	Low risk	106/133 completed trial
Selective reporting (reporting bias)	Unclear risk	No details
Sample size	Unclear risk	50‐199 participants per treatment arm

Open in a new tab

BM: bowel movement; ECOG: Eastern Cooperative Oncology Group; CGIC: Clinical Global Impression of Change; h: hour; n: number of participants; OXN PR: oxycodone/naloxone prolonged release; OXY PR: oxycodone prolonged release; RFBM: rescue‐free bowel movements; SBM: spontaneous bowel movement; SD: standard deviation.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Meissner 2009	Study of people with chronic pain not palliative care or cancer
Mori 2017	Not an RCT
Nadstawek 2008	Study of people with chronic pain not palliative care or cancer
Poelaert 2015	Not an RCT
Vondrackova 2008	Study of people with chronic (low back) pain not palliative care or cancer

Open in a new tab

RCT: randomised controlled trial.

Characteristics of studies awaiting assessment [ordered by study ID]

Webster 2013.

Methods	RCT
Participants	Participants with opioid‐induced constipation. Participants had non‐malignant or cancer‐related pain. No breakdown provided of number with cancer and no subanalysis of effect in group with cancer
Interventions	Naloxegol
Outcomes	Spontaneous bowel movements
Notes	Awaiting responses from authors to clarify population details and further details for analysis

Open in a new tab

RCT: randomised controlled trial.

Characteristics of ongoing studies [ordered by study ID]

Dimitroulis 2014.

Trial name or title	Methylnaltrexone Bromide in the Treatment of Opioid‐Induced Constipation in Lung Cancer Patients
Methods	Single‐centre RCT
Participants	34 participants with a life expectancy of ≥ 3 months receiving treatment for lung cancer. All participants received fentanyl
Interventions	Intervention: methylnaltrexone 12 mg/0.6 mL subcutaneous Comparison: placebo Duration: 4 weeks Drugs administered on alternate days
Outcomes	Laxation
Starting date	Trial completed, no published paper identified
Contact information	Ioannis A Dimitroulis, 6th Pulmonary Department, Sotiria Hospital for Thoracic Diseases, Athens, Greece
Notes

Open in a new tab

JAPIC‐CTI‐132340.

Trial name or title	Phase 3 Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid‐Induced Constipation in Cancer Patients
Methods	RCT
Participants	People with cancer
Interventions	Intervention: naldemedine Comparison: placebo
Outcomes	Efficacy in improving bowel function and safety
Starting date	Study completed 2016, result presented in abstract only, full paper expected
Contact information	Toshiyuki Harada MD, PhD (harada‐toshiyuki@hokkaido.jcho.go.jp)
Notes	Sponsor Shionogi Limited

Open in a new tab

NCT00135577.

Trial name or title	A Double‐Blind, Placebo‐Controlled, Multi‐Centre Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid‐Induced Bowel Dysfunction in Cancer Pain Subjects
Methods	RCT
Participants	People with cancer
Interventions	Intervention: alvimopan Comparison: placebo
Outcomes	Laxation
Starting date	2004
Contact information	Sponsor Cubist, collaborator GlaxoSmithKline
Notes	ID NCT00135577

Open in a new tab

NCT00331045/00101998.

Trial name or title	Trial of Alvimopan Drug for Treatment of Constipation due to Prescription Pain Medication in Cancer Patients
Methods	RCT
Participants	People with cancer
Interventions	Intervention: alvimopan Comparison: placebo
Outcomes	Not stated
Starting date	Start date 2003, completed 2006
Contact information	Funded by Cubist
Notes	IDs NCT00331045 trial terminated early (with 21 participants) "as subject registration did not proceed as expected," NCT00101998 trial completed

Open in a new tab

NCT01438567.

Trial name or title	RCT in Symptoms of Constipation in Subjects with Non‐Malignant or Malignant Pain that Requires Around‐the‐Clock Opioid Therapy taking 50/25‐80/40 mg Twice Daily as Oxycodone/Naloxone Prolonged Release Tablets Compared to Subjects taking 50‐80 mg Twice Daily Oxycodone Prolonged Release Tablets Alone
Methods	RCT
Participants	People with and without cancer pain
Interventions	Intervention: oxycodone/naloxone Comparison: oxycodone alone
Outcomes	Pain and bowel function
Starting date	Clinical trials website reports trial complete, no publication identified
Contact information	Funded by Mundipharma GmbH, no contact details provided on clinical trials website
Notes

Open in a new tab

NCT02321397.

Trial name or title	To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between Oxycodone/naloxone PR Higher Dose & Lower Dose Tablet Strengths in Subjects with Non‐cancer or Cancer Pain
Methods	RCT
Participants	People with and without cancer with pain
Interventions	OXN PR higher‐dose and lower‐dose tablets
Outcomes	Pain and bowel function
Starting date	2014
Contact information	Funded by Mundipharma, no contact details provided on clinical trials website
Notes

Open in a new tab

NCT02574819.

Trial name or title	Trial of Methylnaltrexone in Opioid‐Induced Constipation Patients
Methods	RCT
Participants	People with advanced illness
Interventions	Intervention: Subcutaneous methylnaltrexone Comparison: placebo
Outcomes	Laxation
Starting date	2015
Contact information	Shiying Yu, Professorsyyu@tjh.tjmu.edu.cn
Notes	Sponsors: Jiangsu Chia‐tai Tianqing Pharmaceutical Co, Ltd

Open in a new tab

NCT02745353.

Trial name or title	Naloxegol in Cancer Opioid‐Induced Constipation
Methods	Randomised single‐centre trial
Participants	People with cancer
Interventions	Intervention: naloxegol Comparison: treatment as usual
Outcomes	Laxation, quality of life, and pain
Starting date	May 2016
Contact information	Chelsea Hagmann, chagmann@ucsd.edu
Notes	Sponsor: University of California, Collaborator: Astra Zeneca

Open in a new tab

NCT02839889.

Trial name or title	Tolerability, Safety, and Feasibility of Naloxegol in Patients with Cancer and OIC (Opioid Induced Constipation)
Methods	Randomised multi‐centre trial
Participants	People with cancer
Interventions	Intervention: naloxegol Comparison: placebo
Outcomes	Laxation and pain
Starting date	July 2016
Contact information	Janet Bull, MD, jbull@fourseasonscfl.org
Notes	Sponsor and collaborators: Hospice of Henderson County, Inc and Astra Zeneca

Open in a new tab

Neefjes 2014.

Trial name or title	Clinical Evaluation of the Efficacy of Methylnaltrexone in Resolving Constipation‐Induced by Different Opioid Subtypes Combined with Laboratory Analysis of Immunomodulatory and Antiangiogenic Effects of Methylnaltrexone
Methods	Multi‐centre RCT
Participants	People receiving palliative care with opioid‐induced constipation
Interventions	Intervention: methylnaltrexone Comparison: unclear
Outcomes	Differences in the efficacy of methylnaltrexone prescribed to resolve opioid‐induced constipation between 3 commonly used opioid subtypes: morphine sulphate, oxycodone, and fentanyl
Starting date	Not stated, protocol published in 2014. Trial ongoing as reported December 2015
Contact information	ECW Neefjes, Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands, e.neefjes2@vumc.nl
Notes	ID NCT01955213

Open in a new tab

Peppin 2013.

Trial name or title	Effect of Subcutaneous Methylnaltrexone on Patient‐Reported Outcomes in Advanced Illness Patients with Opioid‐Induced Constipation
Methods	RCT
Participants	People with advanced illness
Interventions	Intervention: methylnaltrexone Comparison: placebo
Outcomes	Participant‐reported outcomes of constipation distress, bowel movement difficulty, and Global Clinical Impression of Change
Starting date	Not stated, conference abstract with findings published in 2013
Contact information	J Peppin. Progenics Pharmaceuticals Inc, Tarrytown, NY sponsored trial
Notes	Did not include results section so unclear if trial is the same as any identified in a full published paper.

Open in a new tab

RCT: randomised controlled trial.

Differences between protocol and review

We included the population of interest in the title.

This review differed in inclusion criteria from the two reviews it is updating (Candy 2011; McNicol 2008). This is in population of interest, which in this review is restricted to cancer and palliative care. In one of the earlier reviews there was no restriction on population (McNicol 2008). Since publication, there are more trials on MOAs for OIBD, particularly in postoperative populations. This current review update was restricted in population to allow us to complete the review in a timely manner. A review on MOAs for OIBD in other populations is planned, to be undertaken by another team that has relevant clinical expertise. This review update also differs in interventions. In one of the earlier reviews the effectiveness of laxatives and the MOA, methylnaltrexone, was explored in palliative care populations (Candy 2011). This current review update included all MOAs to reflect new drug developments. We did not include trials on laxatives in palliative care as the findings of these are reported elsewhere (Candy 2015).

We updated the background section to reflect new research findings.

We updated the methods section to reflect current Cochrane guidelines, in particular in risk of bias and quality assessment. The outcomes of interest differed from previous versions. In part this can be accounted for because the population differed. In the current version, we also extended our search methods to clinical trial registers and online regulatory documents. A previous version of the review (McNicol 2008) used Jadad score to assess trial quality (Jadad 1996). The current review differed as it assessed the risk of bias of trial findings as set out in the current version of the Cochrane Handbook for Systematic Reviews on interventions (Higgins 2011). It also assesses the quality of the evidence using the GRADE system (Guyatt 2013a) and provided 'Summary of findings' tables.

Some of the aspects on reporting in the other earlier version (McNicol 2008) were not relevant in the current update because of updated Cochrane guidelines and inclusion criteria differences. These reasons accounted for differences in the sections on analysis, specifically on unit of analysis issues, missing data, and subgroup analysis. Unlike earlier versions, this review update did not detail how we would assess publication bias, as we were unable to do this analysis because of the limited number of trials.

In this update, we sought to include in addition to trials presented in full journal publication, any online clinical trial results summaries of otherwise unpublished clinical trial or trial data relating to the published trial.

Contributions of authors

In the 2017 review update:

Independent assessment of eligibility of trials in new searches: BC and LJ.

Data extraction: BC and checked by LJ and VV.

Statistical support: VV.

Updating of all review sections was drafted by BC and checked and critiqued by other members of the review update team (LJ, PJL, PS, and VV). This is apart from the 'Summary of findings' tables, which were drafted by VV and checked and critiqued by BC.

Sources of support

Internal sources

No sources of support supplied

External sources

Marie Curie Care, UK.

Supported BC, VV, PS through a departmental programme grant

Declarations of interest

BC: none known.

LJ: none known.

VV: none known.

PJL: none known.

PS: none known; PS is a Professor of palliative medicine at UCL and honorary consultant in palliative medicine at University College Hospital London.

New search for studies and content updated (conclusions changed)

References

References to studies included in this review

Ahmedzai 2012 {published data only}

Ahmedzai SH, Nauck F, Bar‐Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double‐blind, active‐ controlled, double‐dummy, parallel‐group study to determine the safety and efficacy of oxycodone/naloxone prolonged‐release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine 2012;26:50‐60. [DOI] [PMC free article] [PubMed] [Google Scholar]
Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016).
US Food, Drug Administration. Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended‐release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016).

Bull 2015 {published data only}

Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed‐dose subcutaneous methylnaltrexone in patients with advanced illness and opioid‐induced constipation: results of a randomized, placebo‐controlled study and open‐label extension. Journal of Palliative Medicine 2015;18:593‐600. [DOI] [PMC free article] [PubMed] [Google Scholar]

Dupoiron 2017 {published data only}

Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain 2017;21:1‐10. [DOI] [PMC free article] [PubMed] [Google Scholar]

Katakami 2017 {published data only}

Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, et al. Phase IIb randomized, double‐blind, placebo‐controlled study of naldemedine for the treatment of opioid‐induced constipation in patients with cancer. Journal of Clinical Oncology 2017;35(17):1921‐1928. [DOI] [PubMed] [Google Scholar]

Portenoy 2008 {published data only}

Portenoy RK, Thomas J, Moehl Boatwright ML, Galasso FL, Stambler N, Gunten CF, et al. Subcutaneous methylnaltrexone for the treatment of opioid‐induced constipation in patients with advanced illness: a double‐blind, randomised, parallel group, dose‐ranging study. Journal of Pain and Symptom Management 2008;35:458‐68. [DOI] [PubMed] [Google Scholar]

Slatkin 2009 {published data only}

Center for Drug Evaluation and Research. Statistical review. Application 21‐964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008.
European Medicines Agency. Assessment report for Relistor. Procedure No. EMEA/H/C/870. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016).
Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid‐induced constipation in advanced illness patients. Journal of Supportive Oncology 2009;7:39‐46. [PubMed] [Google Scholar]

Sykes 1996 {published data only}

Sykes NP. An investigation of the ability of oral naloxone to correct opioid‐related constipation in patients with advanced cancer. Palliative Medicine 1996;10:135‐44. [DOI] [PubMed] [Google Scholar]

Thomas 2008 {published data only}

Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, et al. Methylnaltrexone treatment of opioid‐induced constipation in patients with advanced illness. Journal of Pain and Symptom Management 2009;38:683‐90. [DOI] [PubMed] [Google Scholar]
Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid‐induced constipation in advanced illness. New England Journal of Medicine 2008;358:2332‐4. [DOI] [PubMed] [Google Scholar]

References to studies excluded from this review

Meissner 2009 {published data only}

Meissner W, Leyendecker P, Mueller‐Lissner S, Nadstawek J, Hopp M, Ruckes C, et al. A randomised controlled trial with prolonged‐release oral oxycodone and naloxone to prevent and reverse opioid‐induced constipation. European Journal of Pain 2009;13:55‐64. [DOI] [PubMed] [Google Scholar]

Mori 2017 {published data only}

Mori M, Ji Y, Kumar S, Ashikaga T, Ades S. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid‐induced constipation (OIC) in cancer patients: an exploratory study. International Journal of Clinical Oncology 2017; Vol. 22, issue 2:397‐404. [DOI] [PubMed]

Nadstawek 2008 {published data only}

Nadstawek J, Leyendecker P, Hopp M, Ruckes C, Wirz S, Fleischer W, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. International Journal of Clinical Practice 2008;62:1159‐67. [DOI] [PMC free article] [PubMed] [Google Scholar]

Poelaert 2015 {published data only}

Poelaert J, Koopmans‐Klein G, Dioh A, Louis F, Gorissen M, Loge D, et al. Treatment with prolonged‐release oxycodone/naloxone improves pain relief and opioid‐induced constipation compared with prolonged‐release oxycodone in patients with chronic severe pain and laxative‐refractory constipation. Clinical Therapeutics 2015;37:784‐92. [DOI] [PubMed] [Google Scholar]

Vondrackova 2008 {published data only}

Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Journal of Pain 2008;9:1144‐54. [DOI] [PubMed] [Google Scholar]

References to studies awaiting assessment

Webster 2013 {published data only}

Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double‐blind, randomized, placebo‐controlled, dose‐escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid‐induced constipation. Pain 2013;154:1542‐50. [DOI] [PubMed] [Google Scholar]

References to ongoing studies

Dimitroulis 2014 {published data only}

Dimitroulis I A. Methylnaltrexone bromide in the treatment of opioid‐induced constipation in lung cancer patients. Is it effective?. Journal of Thoracic Oncology 2014;9:S204. [Google Scholar]

JAPIC‐CTI‐132340 {published data only}

Harada T, Katakami N, Murata T, Shinozakl K, Tsutsumi M, Yokota T, et al. Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid‐induced constipation (OIC) in cancer patients. Journal of Clinical Oncology 2016;34 (Suppl):10016. [Google Scholar]

NCT00135577 {unpublished data only}

NCT00135577. Study 767905/008 extension study: alvimopan for treatment of opioid‐induced bowel dysfunction in cancer pain subjects. clinicaltrials.gov/ct2/show/NCT00135577 Date first received: 26 August 2005.

NCT00331045/00101998 {unpublished data only}

NCT00101998. Study of alvimopan drug for treatment of constipation due to prescription pain medication. clinicaltrials.gov/ct2/show/NCT00101998 Date first received: 19 January 2005.
NCT00331045. Clinical evaluation of alvimopan (SB767905) on constipation and related symptoms associated with opioid. clinicaltrials.gov/ct2/show/NCT00331045 Date first received: 29 May 2006.

NCT01438567 {unpublished data only}

NCT01438567. A study to demonstrate improvement in symptoms of constipation in subjects that require around‐the‐clock opioid pain killer therapy. clinicaltrials.gov/ct2/show/NCT01438567 Date first received: 22 September 2011.

NCT02321397 {published data only}

NCT02321397. To demonstrate equivalence in analgesic efficacy & bowel function between OXN PR higher dose & lower dose tablet strengths in subjects with non‐cancer or cancer pain. clinicaltrials.gov/ct2/show/NCT02321397 Date first received: 22 December 2014.

NCT02574819 {published data only}

NCT02574819. Study of methylnaltrexone in opioid‐induced constipation patients. clinicaltrials.gov/ct2/show/NCT02574819 Date first received: 14 October 2015.

NCT02745353 {published data only}

NCT02745353. Naloxegol in cancer opioid‐induced constipation. clinicaltrials.gov/ct2/show/NCT02745353 Date first received: 20 April 2016.

NCT02839889 {published data only}

NCT02839889. Tolerability, safety, and feasibility of naloxegol in patients with cancer and OIC (opioid induced constipation). clinicaltrials.gov/ct2/show/NCT02839889 Date first received: 21 July 2016.

Neefjes 2014 {published data only}

Neefjes EC, Vorst MJ, Boddaert MS, Zuurmond WW, Vliet HJ, Beeker A, et al. Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliative Care 2014;13:42. [DOI] [PMC free article] [PubMed] [Google Scholar]

Peppin 2013 {unpublished data only}

Peppin. RCT: methylnaltrexone in patients with advanced illness with opioid induced constipation. Clinicaltrials.gov 2013.

Additional references

Bader 2012

Bader S, Weber M, Becker G. Is the pharmacological treatment of constipation in palliative care evidence based? A systematic literature review. Der Schmerz 2012;26:568‐86. [DOI] [PubMed] [Google Scholar]

Bader 2013

Bader S, Durk T, Becker G. Methylnaltrexone for the treatment of opioid‐induced constipation. Expert Review of Gastroenterology & Hepatology 2013;7:13‐26. [DOI] [PubMed] [Google Scholar]

Brown 1985

Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24:181‐91. [DOI] [PubMed] [Google Scholar]

Camilleri 2011

Camilleri 2011. Opioid‐induced constipation: challenges and therapeutic opportunities. American Journal of Gastroenterology 2011;106:835‐42. [DOI] [PubMed] [Google Scholar]

Camilleri 2014

Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid‐induced constipation. Neurogastroenterology & Motility 2014;26:1386‐95. [DOI] [PMC free article] [PubMed] [Google Scholar]

Candy 2015

Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD003448.pub4] [DOI] [PMC free article] [PubMed] [Google Scholar]

Caraceni 2012

Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence‐based recommendations from the EAPC. Lancet Oncology 2012;13:e58‐68. [DOI] [PubMed] [Google Scholar]

Clark 2014

Clark K, Currow DC. Methylnaltrexone in palliative care: further research is needed. Journal of Pain and Symptom Management 2014;47:e5‐6. [DOI] [PubMed] [Google Scholar]

Cook 2008

Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, et al. Gastrointestinal side effects in chronic opioid users: results from a population‐based survey. Alimentary Pharmacology & Therapeutics 2008;27:1224‐32. [DOI] [PubMed] [Google Scholar]

Coyne 2014

Coyne KS, LoCasale RJ, Datto CJ. Opioid‐induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient‐reported outcomes and retrospective chart review. Clinicoeconomic Outcomes Research 2014;6:269‐81. [DOI] [PMC free article] [PubMed] [Google Scholar]

Deeks 2006

Deeks JJ, Higgins JP, Altman DG, editor(s). Analysing and presenting results. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. 4.2.6. Chichester, UK: Wiley‐Blackwell, 2006. [Google Scholar]

Diego 2011

Diego L, Atayee R, Helmons P, Hsiao G, Gunten CF. Novel opioid antagonists for opioid‐induced bowel dysfunction. Expert Opinion on Investigational Drugs 2011;20:1047‐56. [DOI] [PubMed] [Google Scholar]

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34. [DOI] [PMC free article] [PubMed] [Google Scholar]

Ford 2013

Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid‐induced constipation: systematic review and meta‐analysis. American Journal of Gastroenterology 2013;108:1566‐74. [DOI] [PubMed] [Google Scholar]

Guyatt 2013a

Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66:151‐7. [DOI] [PubMed] [Google Scholar]

Guyatt 2013b

Guyatt GH, Oxman AD, Santesso N, Helfand M, Kunz R, Brozek J, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology 2013;66:158‐72. [DOI] [PubMed] [Google Scholar]

Higgins 2011

Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Jadad 1996

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Controlled Clinical Trials 1996;17:1‐12. [DOI] [PubMed] [Google Scholar]

Janku 2015

Janku F, Moss J, Karp D, Singleton P, Johnson L. Treatment with methylnaltrexone is associated with increased survival in patients with advanced refractory cancers treated for opioid induced constipation. European Journal of Cancer 2015;51:S235. [Google Scholar]

Ketwaroo 2013

Ketwarro GA, Cheng V, Lembo A. Opioid‐induced bowel dysfunction. Current Gastroenterology Reports 2013;15:344. [DOI] [PMC free article] [PubMed] [Google Scholar]

Kumar 2012

Kumar NB. Dysfunction of the Bowel/Constipation. Nutritional Management of Cancer Treatment Effects. Berlin/Heidelberg: Springer‐Verlag, 2012. [Google Scholar]

Leppert 2010

Leppert W. The role of opioid receptor antagonists in the treatment of opioid‐induced constipation: a review. Advances in Therapy 2010;27:714‐30. [DOI] [PubMed] [Google Scholar]

Leppert 2015

Leppert W. Emerging therapies for patients with symptoms of opioid‐induced bowel dysfunction. Drug Design, Development and Therapy 2015;9:2215‐31. [DOI] [PMC free article] [PubMed] [Google Scholar]

Manjiani 2014

Manjiani D, Paul DB, Kunnumpurath S, Kaye AD, Vadivelu N. Availability and utilization of opioids for pain management: global issues. Ochsner Journal 2014;14:208‐15. [PMC free article] [PubMed] [Google Scholar]

Marderstein 2008

Marderstein EL, Delaney CP. Management of postoperative ileus: focus on alvimopan. Therapeutics and Clinical Risk Management 2008;4:965‐73. [DOI] [PMC free article] [PubMed] [Google Scholar]

Mehta 2016

Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S. Efficacy of methylnaltrexone for the treatment of opioid‐induced constipation: a meta‐analysis and systematic review. Postgraduate Medicine 2016;128:282‐9. [DOI] [PubMed] [Google Scholar]

Merck 2015

Pharmaceutical Manufacturing Research Services. Highlights of prescribing information, 2015. www.merck.com/product/usa/pi_circulars/e/entereg/entereg_pi.pdf (date accessed 28 March 2017).

NICE 2012

National Institute for Health and Care excellence. Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults, 2012. www.nice.org.uk/guidance/cg140/resources (date accessed 17 November 2016).

NICE 2013

National Institute for Health and Care excellence. Methylnaltrexone for treating opioid‐induced bowel dysfunction in people with advanced illness receiving palliative care (suspended appraisal). NICE technology appraisal guidance (TA277), 2013. www.nice.org.uk/guidance/ta277 (accessed 19 April 2017).

Panchal 2007

Panchal SJ, Muller‐Schwefe P, Wurzelmann JI. Opioid‐induced bowel dysfunction: prevalence, pathophysiology and burden. International Journal of Clinical Practice 2007;61:1181‐7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Pappagallo 2001

Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. American Journal of Surgery 2001;182 (Suppl):11‐18S. [DOI] [PubMed] [Google Scholar]

Pizzi 2012

Pizzi LT, Toner R, Foley K, Thomson E, Chow W, Kim M, et al. Relationship between potential opioid‐related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy 2012;32:502‐14. [DOI] [PubMed] [Google Scholar]

Pritchard 2015

Pritchard D, Bharucha A. Management of opioid‐induced constipation for people in palliative care. International Journal of Palliative Nursing 2015;21:272‐80. [DOI] [PubMed] [Google Scholar]

Roberts 2015

Roberts I, Ker K. How systematic reviews cause research waste. Lancet 2015;386:1536. [DOI] [PubMed] [Google Scholar]

Schulz 2010

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 2010;152:1‐7. [DOI] [PubMed] [Google Scholar]

Scottish Palliative Care Guidelines 2014

NHS Scotland. Scottish Palliative Care Guidelines: about the guidelines, 2014. www.palliativecareguidelines.scot.nhs.uk/guidelines (accessed 17 November 2016).

Siemens 2015

Siemens W, Gaertner J, Becker G. Advances in pharmacotherapy for opioid‐induced constipation ‐ a systematic review. Expert Opinion on Pharmacotherapy 2015;16:515‐32. [DOI] [PubMed] [Google Scholar]

Sterne 2011

Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Sykes 1998

Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliative Medicine 1998;12:375‐82. [DOI] [PubMed] [Google Scholar]

Wang 2013

Wang C‐Z, Yuan C‐S. Pharmacologic treatment of opioid‐induced constipation. Drugs 2013;22:1225‐7. [DOI] [PubMed] [Google Scholar]

WHO 2016

World Health Organization. WHO's cancer pain ladder for adults, 2016. who.int/cancer/palliative/painladder/en/ (accessed 17 November 2016).

Zhang 2013

Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta‐analyses: a meta‐epidemiological study. Critical Care 2013;17:R2. [DOI] [PMC free article] [PubMed] [Google Scholar]

References to other published versions of this review

Candy 2011

Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD003448.pub3] [DOI] [PubMed] [Google Scholar]

McNicol 2008

McNicol ED, Boyce D, Schumann R, Carr DB. Mu‐opioid antagonists for opioid‐induced bowel dysfunction. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006332.pub2] [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0001] Ahmedzai SH, Nauck F, Bar‐Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double‐blind, active‐ controlled, double‐dummy, parallel‐group study to determine the safety and efficacy of oxycodone/naloxone prolonged‐release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine 2012;26:50‐60. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0002] Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016).

[CD006332-bib-0003] US Food, Drug Administration. Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended‐release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016).

[CD006332-bib-0004] Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed‐dose subcutaneous methylnaltrexone in patients with advanced illness and opioid‐induced constipation: results of a randomized, placebo‐controlled study and open‐label extension. Journal of Palliative Medicine 2015;18:593‐600. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0005] Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain 2017;21:1‐10. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0006] Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, et al. Phase IIb randomized, double‐blind, placebo‐controlled study of naldemedine for the treatment of opioid‐induced constipation in patients with cancer. Journal of Clinical Oncology 2017;35(17):1921‐1928. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0007] Portenoy RK, Thomas J, Moehl Boatwright ML, Galasso FL, Stambler N, Gunten CF, et al. Subcutaneous methylnaltrexone for the treatment of opioid‐induced constipation in patients with advanced illness: a double‐blind, randomised, parallel group, dose‐ranging study. Journal of Pain and Symptom Management 2008;35:458‐68. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0008] Center for Drug Evaluation and Research. Statistical review. Application 21‐964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008.

[CD006332-bib-0009] European Medicines Agency. Assessment report for Relistor. Procedure No. EMEA/H/C/870. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016).

[CD006332-bib-0010] Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid‐induced constipation in advanced illness patients. Journal of Supportive Oncology 2009;7:39‐46. [PubMed] [Google Scholar]

[CD006332-bib-0011] Sykes NP. An investigation of the ability of oral naloxone to correct opioid‐related constipation in patients with advanced cancer. Palliative Medicine 1996;10:135‐44. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0012] Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, et al. Methylnaltrexone treatment of opioid‐induced constipation in patients with advanced illness. Journal of Pain and Symptom Management 2009;38:683‐90. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0013] Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid‐induced constipation in advanced illness. New England Journal of Medicine 2008;358:2332‐4. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0014] Meissner W, Leyendecker P, Mueller‐Lissner S, Nadstawek J, Hopp M, Ruckes C, et al. A randomised controlled trial with prolonged‐release oral oxycodone and naloxone to prevent and reverse opioid‐induced constipation. European Journal of Pain 2009;13:55‐64. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0015] Mori M, Ji Y, Kumar S, Ashikaga T, Ades S. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid‐induced constipation (OIC) in cancer patients: an exploratory study. International Journal of Clinical Oncology 2017; Vol. 22, issue 2:397‐404. [DOI] [PubMed]

[CD006332-bib-0016] Nadstawek J, Leyendecker P, Hopp M, Ruckes C, Wirz S, Fleischer W, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. International Journal of Clinical Practice 2008;62:1159‐67. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0017] Poelaert J, Koopmans‐Klein G, Dioh A, Louis F, Gorissen M, Loge D, et al. Treatment with prolonged‐release oxycodone/naloxone improves pain relief and opioid‐induced constipation compared with prolonged‐release oxycodone in patients with chronic severe pain and laxative‐refractory constipation. Clinical Therapeutics 2015;37:784‐92. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0018] Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Journal of Pain 2008;9:1144‐54. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0019] Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double‐blind, randomized, placebo‐controlled, dose‐escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid‐induced constipation. Pain 2013;154:1542‐50. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0020] Dimitroulis I A. Methylnaltrexone bromide in the treatment of opioid‐induced constipation in lung cancer patients. Is it effective?. Journal of Thoracic Oncology 2014;9:S204. [Google Scholar]

[CD006332-bib-0021] Harada T, Katakami N, Murata T, Shinozakl K, Tsutsumi M, Yokota T, et al. Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid‐induced constipation (OIC) in cancer patients. Journal of Clinical Oncology 2016;34 (Suppl):10016. [Google Scholar]

[CD006332-bib-0022] NCT00135577. Study 767905/008 extension study: alvimopan for treatment of opioid‐induced bowel dysfunction in cancer pain subjects. clinicaltrials.gov/ct2/show/NCT00135577 Date first received: 26 August 2005.

[CD006332-bib-0023] NCT00101998. Study of alvimopan drug for treatment of constipation due to prescription pain medication. clinicaltrials.gov/ct2/show/NCT00101998 Date first received: 19 January 2005.

[CD006332-bib-0024] NCT00331045. Clinical evaluation of alvimopan (SB767905) on constipation and related symptoms associated with opioid. clinicaltrials.gov/ct2/show/NCT00331045 Date first received: 29 May 2006.

[CD006332-bib-0025] NCT01438567. A study to demonstrate improvement in symptoms of constipation in subjects that require around‐the‐clock opioid pain killer therapy. clinicaltrials.gov/ct2/show/NCT01438567 Date first received: 22 September 2011.

[CD006332-bib-0026] NCT02321397. To demonstrate equivalence in analgesic efficacy & bowel function between OXN PR higher dose & lower dose tablet strengths in subjects with non‐cancer or cancer pain. clinicaltrials.gov/ct2/show/NCT02321397 Date first received: 22 December 2014.

[CD006332-bib-0027] NCT02574819. Study of methylnaltrexone in opioid‐induced constipation patients. clinicaltrials.gov/ct2/show/NCT02574819 Date first received: 14 October 2015.

[CD006332-bib-0028] NCT02745353. Naloxegol in cancer opioid‐induced constipation. clinicaltrials.gov/ct2/show/NCT02745353 Date first received: 20 April 2016.

[CD006332-bib-0029] NCT02839889. Tolerability, safety, and feasibility of naloxegol in patients with cancer and OIC (opioid induced constipation). clinicaltrials.gov/ct2/show/NCT02839889 Date first received: 21 July 2016.

[CD006332-bib-0030] Neefjes EC, Vorst MJ, Boddaert MS, Zuurmond WW, Vliet HJ, Beeker A, et al. Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliative Care 2014;13:42. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0031] Peppin. RCT: methylnaltrexone in patients with advanced illness with opioid induced constipation. Clinicaltrials.gov 2013.

[CD006332-bib-0032] Bader S, Weber M, Becker G. Is the pharmacological treatment of constipation in palliative care evidence based? A systematic literature review. Der Schmerz 2012;26:568‐86. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0033] Bader S, Durk T, Becker G. Methylnaltrexone for the treatment of opioid‐induced constipation. Expert Review of Gastroenterology & Hepatology 2013;7:13‐26. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0034] Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24:181‐91. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0035] Camilleri 2011. Opioid‐induced constipation: challenges and therapeutic opportunities. American Journal of Gastroenterology 2011;106:835‐42. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0036] Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid‐induced constipation. Neurogastroenterology & Motility 2014;26:1386‐95. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0037] Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD003448.pub4] [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0038] Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence‐based recommendations from the EAPC. Lancet Oncology 2012;13:e58‐68. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0039] Clark K, Currow DC. Methylnaltrexone in palliative care: further research is needed. Journal of Pain and Symptom Management 2014;47:e5‐6. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0040] Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, et al. Gastrointestinal side effects in chronic opioid users: results from a population‐based survey. Alimentary Pharmacology & Therapeutics 2008;27:1224‐32. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0041] Coyne KS, LoCasale RJ, Datto CJ. Opioid‐induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient‐reported outcomes and retrospective chart review. Clinicoeconomic Outcomes Research 2014;6:269‐81. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0042] Deeks JJ, Higgins JP, Altman DG, editor(s). Analysing and presenting results. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. 4.2.6. Chichester, UK: Wiley‐Blackwell, 2006. [Google Scholar]

[CD006332-bib-0043] Diego L, Atayee R, Helmons P, Hsiao G, Gunten CF. Novel opioid antagonists for opioid‐induced bowel dysfunction. Expert Opinion on Investigational Drugs 2011;20:1047‐56. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0044] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0045] Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid‐induced constipation: systematic review and meta‐analysis. American Journal of Gastroenterology 2013;108:1566‐74. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0046] Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66:151‐7. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0047] Guyatt GH, Oxman AD, Santesso N, Helfand M, Kunz R, Brozek J, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology 2013;66:158‐72. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0048] Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

[CD006332-bib-0049] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Controlled Clinical Trials 1996;17:1‐12. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0050] Janku F, Moss J, Karp D, Singleton P, Johnson L. Treatment with methylnaltrexone is associated with increased survival in patients with advanced refractory cancers treated for opioid induced constipation. European Journal of Cancer 2015;51:S235. [Google Scholar]

[CD006332-bib-0051] Ketwarro GA, Cheng V, Lembo A. Opioid‐induced bowel dysfunction. Current Gastroenterology Reports 2013;15:344. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0052] Kumar NB. Dysfunction of the Bowel/Constipation. Nutritional Management of Cancer Treatment Effects. Berlin/Heidelberg: Springer‐Verlag, 2012. [Google Scholar]

[CD006332-bib-0053] Leppert W. The role of opioid receptor antagonists in the treatment of opioid‐induced constipation: a review. Advances in Therapy 2010;27:714‐30. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0054] Leppert W. Emerging therapies for patients with symptoms of opioid‐induced bowel dysfunction. Drug Design, Development and Therapy 2015;9:2215‐31. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0055] Manjiani D, Paul DB, Kunnumpurath S, Kaye AD, Vadivelu N. Availability and utilization of opioids for pain management: global issues. Ochsner Journal 2014;14:208‐15. [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0056] Marderstein EL, Delaney CP. Management of postoperative ileus: focus on alvimopan. Therapeutics and Clinical Risk Management 2008;4:965‐73. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0057] Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S. Efficacy of methylnaltrexone for the treatment of opioid‐induced constipation: a meta‐analysis and systematic review. Postgraduate Medicine 2016;128:282‐9. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0058] Pharmaceutical Manufacturing Research Services. Highlights of prescribing information, 2015. www.merck.com/product/usa/pi_circulars/e/entereg/entereg_pi.pdf (date accessed 28 March 2017).

[CD006332-bib-0059] National Institute for Health and Care excellence. Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults, 2012. www.nice.org.uk/guidance/cg140/resources (date accessed 17 November 2016).

[CD006332-bib-0060] National Institute for Health and Care excellence. Methylnaltrexone for treating opioid‐induced bowel dysfunction in people with advanced illness receiving palliative care (suspended appraisal). NICE technology appraisal guidance (TA277), 2013. www.nice.org.uk/guidance/ta277 (accessed 19 April 2017).

[CD006332-bib-0061] Panchal SJ, Muller‐Schwefe P, Wurzelmann JI. Opioid‐induced bowel dysfunction: prevalence, pathophysiology and burden. International Journal of Clinical Practice 2007;61:1181‐7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0062] Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. American Journal of Surgery 2001;182 (Suppl):11‐18S. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0063] Pizzi LT, Toner R, Foley K, Thomson E, Chow W, Kim M, et al. Relationship between potential opioid‐related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy 2012;32:502‐14. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0064] Pritchard D, Bharucha A. Management of opioid‐induced constipation for people in palliative care. International Journal of Palliative Nursing 2015;21:272‐80. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0065] Roberts I, Ker K. How systematic reviews cause research waste. Lancet 2015;386:1536. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0066] Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 2010;152:1‐7. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0067] NHS Scotland. Scottish Palliative Care Guidelines: about the guidelines, 2014. www.palliativecareguidelines.scot.nhs.uk/guidelines (accessed 17 November 2016).

[CD006332-bib-0068] Siemens W, Gaertner J, Becker G. Advances in pharmacotherapy for opioid‐induced constipation ‐ a systematic review. Expert Opinion on Pharmacotherapy 2015;16:515‐32. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0069] Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

[CD006332-bib-0070] Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliative Medicine 1998;12:375‐82. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0071] Wang C‐Z, Yuan C‐S. Pharmacologic treatment of opioid‐induced constipation. Drugs 2013;22:1225‐7. [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0072] World Health Organization. WHO's cancer pain ladder for adults, 2016. who.int/cancer/palliative/painladder/en/ (accessed 17 November 2016).

[CD006332-bib-0073] Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta‐analyses: a meta‐epidemiological study. Critical Care 2013;17:R2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CD006332-bib-0074] Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD003448.pub3] [DOI] [PubMed] [Google Scholar]

[CD006332-bib-0075] McNicol ED, Boyce D, Schumann R, Carr DB. Mu‐opioid antagonists for opioid‐induced bowel dysfunction. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006332.pub2] [DOI] [PubMed] [Google Scholar]

PERMALINK

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care

Bridget Candy

Louise Jones

Victoria Vickerstaff

Philip J Larkin

Patrick Stone

Abstract

Background

Objectives

Search methods

Selection criteria

Data collection and analysis

Main results

Authors' conclusions

Plain language summary

Summary of findings

Background

Description of the condition

Description of the intervention

How the intervention might work

Why it is important to do this review

Objectives

Methods

Criteria for considering studies for this review

Types of studies

Types of participants

Types of interventions

Types of outcome measures

Primary outcomes

Secondary outcomes

Search methods for identification of studies

Electronic searches

Searching other resources

Data collection and analysis

Selection of studies

Data extraction and management

Assessment of risk of bias in included studies

Measures of treatment effect

Dichotomous data

Continuous data

Qualitative evidence

Unit of analysis issues

Dealing with missing data

Assessment of heterogeneity

Assessment of reporting biases

Data synthesis

Subgroup analysis and investigation of heterogeneity

Sensitivity analysis

Quality of evidence

'Summary of findings' table

Results

Description of studies

Results of the search

1.

Included studies

Excluded studies

Ongoing studies

Studies awaiting classification

Risk of bias in included studies

2.

3.

Allocation

Blinding

Incomplete outcome data

Selective reporting

Other potential sources of bias

Effects of interventions

Summary of findings for the main comparison. Naldemedine compared to placebo for opioid‐induced bowel dysfunction in cancer and people receiving palliative care.

Summary of findings 2. Lower‐dose naldemedine compared to higher‐dose naldemedine for opioid‐induced bowel dysfunction in cancer and people receiving palliative care.

Summary of findings 3. Naloxone compared with placebo for cancer and people receiving palliative care with opioid‐induced bowel dysfunction.

Summary of findings 4. Oxycodone/naloxone prolonged release tablets compared with oxycodone prolonged‐released tablets for opioid‐induced bowel dysfunction.

Summary of findings 5. Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in cancer and people receiving palliative care.

Summary of findings 6. Lower‐dose methylnaltrexone compared to higher‐dose methylnaltrexone for opioid‐induced bowel dysfunction in cancer and people receiving palliative care.

Naldemedine

Primary outcomes

Laxation response

Effect on analgesia

Serious adverse events

Number and type of adverse events